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0.4	Abstract	
	
Due	to	the	epidemiological	transition,	diabetes	prevalence	in	South	Africa	is	increasing,	while	
HIV	prevalence	remains	high.	Diabetes,	along	with	HIV,	has	been	found	to	be	a	significant	risk	
factor	for	the	development	of	tuberculosis.	Early	detection	and	treatment	of	tuberculosis	is	
essential	to	prevent	unwarranted	morbidity	and	mortality.	This	hinges	on	efficient	diagnostic	
methods	and	tools.	The	chest	radiograph	remains	a	cornerstone	in	pulmonary	tuberculosis	
diagnosis,	especially	in	those	where	microbiological	evidence	of	disease	is	lacking.		
	
A	study	was	conducted	to	investigate	the	chest	radiographic	presentation	of	pulmonary	
tuberculosis	in	patients	with	diabetes,	as	well	as	to	analyse	the	effect	of	HIV	comorbidity	on	
this	association.	The	study	was	conducted	in	Khayelitsha,	Cape	Town,	an	area	with	a	high	
tuberculosis,	HIV	and	diabetes	burden.	A	literature	review	was	conducted	to	identify	the	key	
features	of	pulmonary	tuberculosis	on	chest	radiograph	for	patients	with	diabetes	and	HIV.	
We	found	that	patients	with	diabetes	were	more	likely	to	have	lower	lung	field	infiltrates	and	
increased	cavitation,	with	glycaemic	control	affecting	the	presence	of	these	findings.	Patients	
with	HIV	presented	more	often	with	features	of	primary	tuberculosis	on	chest	radiograph,	
namely	hilar	and/or	mediastinal	adenopathy,	diffuse	reticulonodular	infiltrate,	and	lower	lung	
field	(LLF)	infiltrates	and	cavities.	These	features	were	influenced	by	degree	of	
immunosuppression.	This	review	also	found	that	there	was	no	literature	describing	the	
influence	of	HIV	on	the	chest	radiographic	features	of	tuberculosis	in	patients	with	diabetes.		
	
This	study	was	conducted	between	June	2013	-	October	2015,	where	377	patients	with	
pulmonary	tuberculosis,	from	Ubuntu	and	Site	B	primary	care	clinics	in	Khayelitsha,	
underwent	posterior-anterior	chest	radiography.	Chest	radiographs	were	read	using	a	CRRS	
tool.		
	
Participants	with	diabetes	and	tuberculosis	(TBDM)	had	a	higher	proportion	of	lower	lung	
field	opacification	(76,2%:	95%	CI:	56,3	–	96,1)	and	were	3,92	times	more	likely	to	have	LLF	
cavitations	than	patients	with	TB	only.	TBDM	participants	with	HbA1c	levels	over	10%	had	
more	frequent	LLF	involvement	overall	(90,9%	vs	61,9%	p=0,052)	and	isolated	LLF	
involvement	(27,3%	vs	3,6%;	p=	0,019)	than	TB	only	participants.	Both	TBDM	and	TBDM	
	 ix	
participants	with	HIV	(TBDMHIV)	had	higher	proportions	of	isolated	LLF	lesions	as	compared	
to	TB	only	participants	(14,3%	vs	3,6%;	p=0,093	and	15,2%	vs	3,6%;	p	=	0,039,	respectively).	
As	CD4	counts	increased,	there	was	an	upward	trend	towards	an	increase	in	the	proportion	
of	cavitations	for	TBDMHIV	participants,	but	this	was	not	evident	in	participants	with	TB	and	
HIV	(TBHIV).				
	
This	study	confirms	the	atypical	nature	of	chest	radiograph	in	persons	with	TBDM,	TBHIV	and	
TBDMHIV,	with	diabetes	driving	the	presence	of	lower	lung	field	involvement.	These	findings	
can	be	used	in	bi-directional	screening	algorithms	for	patients	with	diabetes,	with	or	without	
HIV	and	highlights	the	important	role	of	radiographic	examination	in	pulmonary	tuberculosis. 	 	
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Part	A:	Protocol	
	
A.1	Introduction	
	
A.1.1	Background	
Despite	advances	in	scientific	research,	including	improved	diagnostic	technologies,	
tuberculosis	(TB)	remains	a	leading	cause	of	death	globally,	with	9.6	million	incident	cases	
and	1.5	million	dying	of	TB	in	2014(1).	While	efforts	have	been	made	to	curb	the	epidemic	
through	the	roll-out	of	GeneXpert	diagnostic	tests,	TB	case	notification	and	mortality	remains	
high,	and	South	Africa	remains	the	3rd	highest	burden	TB	country	around	the	world(1).	
Human	immunodeficiency	virus	(HIV)	is	the	strongest	known	risk	factor	for	TB(2)	and	
considerable	attention	has	been	paid	to	integration	of	HIV/TB	services,	and	roll-out	of	
antiretroviral	therapy	in	order	to	decrease	TB	risk	and	improve	TB	outcomes.	Although	
advances	have	been	made,	TB	incidence	remains	high	and	treatment	success	sub-optimal.	
There	is	therefore	a	need	for	research	on	other	risk	factors,	largely	neglected	to	date	in	TB	
national	programs,	that	contribute	to	an	increased	TB	risk	and	poorer	clinical	outcomes.		
	
Rapid	urbanization	and	epidemiological	transition	in	South	Africa	has	been	accompanied	by	
decreased	physical	activity,	obesity,	increased	consumption	of	processed	foods,	and	has	
contributed	to	an	emerging	epidemic	of	non-communicable	diseases,	such	as	Type	2	
Diabetes	Mellitus	(T2DM)(3).	In	Khayelitsha,	the	setting	for	this	study,	the	prevalence	of	
T2DM	is	13%	among	the	population(4).	The	association	between	TB	and	diabetes	(DM),	and	
the	need	for	integration	of	services,	has	been	recently	highlighted	by	the	World	Health	
Organisation	(WHO)	Collaborative	Framework	for	Care	and	Control	of	Tuberculosis	and	
Diabetes(5).	From	a	systematic	review	of	13	observational	studies,	it	has	been	suggested	that	
persons	with	diabetes	have	a	3-fold	increased	risk	of	TB,	especially	in	regions	with	high	TB	
incidence(6).		
	
	
	
	
	 2	
A.1.2	Problem	statement	
The	chest	radiograph	is	still	a	valuable	TB	diagnostic	tool.	It	is	utilized	when	first	line	sputum	
testing	is	negative,	unavailable	or	indeterminate.	However,	chest	radiograph	diagnosis	can	be	
difficult,	due	to	inter-patient	variability	of	chest	radiograph	manifestations,	and	patient	
characteristics	such	as	age,	sex,	immune	status	and	time	to	diagnosis(7,	8).	The	resulting	
atypical	presentations	may	confound	and	delay	diagnosis.		
	
Compounding	the	increased	risk	of	TB	in	DM	is	the	atypical	clinical	presentation	of	persons	
with	DM	and	TB	(TBDM).	Chest	radiographs	of	TBDM	patients	have	been	noted	to	be	
dissimilar	to	normoglycaemic	patients	with	TB.	Persons	with	diabetes	are	more	likely	to	have	
lower	lobe	opacification,	multiple	cavities	and	larger	cavities(9-12).	Glycaemic	control	
appears	to	correlate	with	worsened	manifestations	on	chest	radiographs(9).	This	atypical	
presentation	may	delay	diagnosis	and	treatment	of	TB	in	persons	with	DM,	and	potentially	
leading	to	worsened	morbidity	and	mortality.			
	
Numerous	studies	have	compared	the	chest	radiographs	of	persons	with	DM	and	
normoglycaemic	patients	with	TB,	however,	in	our	setting	HIV	is	also	prevalent.	The	
characteristics	of	chest	radiographs	among	patients	with	HIV	and	TB	are	well	
documented(13).	In	this	study,	we	wish	not	only	to	describe	the	characteristics	of	chest	
radiographs	of	patients	with	diabetes	and	TB,	but	also	to	compare	this	to	patients	co-infected	
with	HIV.			
	
A.1.3	Research	question	
In	patients	who	were	recruited	as	part	of	a	larger	TB	and	DM	study	in	Khayelitsha,	is	an	
atypical	chest	radiographic	presentation	of	pulmonary	TB	more	common	in	adult	TB	patients	
with	DM	when	compared	to	those	without	DM?	
	
Secondary	Research	question:	
How	does	HIV	co-infection	influence	this	presentation	of	pulmonary	TB	in	TB	and	TBDM	
patients?		
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A.1.4	Research	justification	
Patients	with	diabetes	and	tuberculosis	may	have	features	on	chest	radiograph	that	are	
unusual	and	may	be	overlooked	at	presentation,	leading	to	misdiagnosis.	These	radiograph	
features	may	also	be	more	severe	in	TBDM	patients,	than	in	normoglycaemic	tuberculosis	
patients.	With	HIV	infection	also	affecting	radiographic	presentation	of	TB,	the	HIV	status	of	
the	TBDM	patient	may	further	augment	the	atypical	findings	on	the	chest	radiograph.		
	
A.1.5	Objectives	
• Describe	unique	radiographic	features	of	chest	radiographs	of	TBDM	patients;	
• To	compare	the	radiographic	features	of	chest	radiographs	of	TBDM	patients	
and	normoglycaemic	TB	patients;	
• To	compare	radiographic	features	of	TBDM	patients	with	and	without	HIV	and	
by	doing	so	establish	the	effect	of	HIV	on	these	features.			
	
A.2	Methodology	
	 	
A.2.1	Study	design	
This	is	a	retrospective	cross-sectional	study	where	chest	radiographs	of	HIV	infected	and	
uninfected	patients	with	confirmed	PTB	will	be	collated	from	a	larger	TBDM	prevalence	study	
(HREC	REF	NO:	403/2011)	investigating	the	prevalence	of	diabetes	amongst	TB	patients	and	
TB	amongst	patients	with	diabetes	in	Khayelitsha,	Cape	Town.	As	part	of	this	parent	study	
participants	underwent	chest	radiography	at	time	of	TB	screening.	These	chest	radiographs	
will	be	read	and	reported	by	two	clinicians,	a	research	medical	officer	and	a	radiologist	-	not	
involved	in	care	of	patients	and	truly	blinded	to	HIV	or	DM	status.	
	
A.2.2	Population	and	sampling	
	
A.2.2.1	Characteristics	of	the	study	population	
Participants	were	be	recruited	from	Ubuntu	TB	and	ARV	clinic,	as	well	as	Site	B	
Community	Health	Centre	in	Khayelitsha	as	part	of	the	larger	study.	All	participants	
who	were	diagnosed	with	active	pulmonary	TB	as	per	national	protocol	(see	TB	case	
definition	below)(14)	will	be	included	in	this	study	sample.	Khayelitsha	is	a	peri-urban	
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township	with	a	population	of	approximately	500,000	people.	The	TB	case	notification	
rate	is	>1600/100	000	with	an	antenatal	HIV	prevalence	of	28%(15).	The	age	
standardized	DM	prevalence	in	Khayelitsha	is	13.1%	(95%	CI:	11.0–15.1%)	(4).		
Participants	were	recruited	between	July	2013	and	July	2015.		
	
A.2.2.2	Parent	study	procedures	
	
This	parent	study	consisted	of	two	arms.	Arm	A	was	a	case	control	study	screening	
patients	who	presented	to	Ubuntu	TB	and	ARV	clinic	with	respiratory	symptoms	for	
TB,	investigating	the	prevalence	of	diabetes	in	TB	patients.	Arm	B	was	a	cross	
sectional	component	screening	known	diabetes	patients	at	Site	B	Community	Health	
Centre	for	TB,	to	investigate	TB	prevalence	in	patients	with	diabetes.	Flow	diagrams	
for	each	study	arm	are	shown	below.	All	participants	in	both	arms	were	offered	HIV	
screening	using	a	rapid	whole	blood	finger	prick	antibody	diagnostic	tests.		
	
Figure	A-1:	Study	Flow	Arm	A	
	
	
	
	
	
Consecutive	adult	
patients	presenting	
with	respiratory	
symptoms	to	TB	clinic
TB	screening	as	per	
national	protocol
All	participants	
screened	for	DM
Diagnosed	with	PTB
Chest	radiograph	
conducted	
No	PTB	diagnosed
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Figure	A-2:	Study	Flow	Arm	B	
	
	
	
A.2.2.3	Case	definitions	
	
The	National	TB	protocol	TB	case	definition	was	used(14):		
1)	smear	microscopy	positive	for	acid-fast	bacilli;	
2)	isolation	or	identification	of	Mycobacterium	tuberculosis	by	culture	or	
Genexpert;			
3)	patients	with	compatible	clinical	signs	and	symptoms	(including	typical	
chest	radiograph)	and	resolution	of	symptoms	after	TB	treatment.		
	 	
Participants	who	screened	microbiologically	negative	for	PTB,	as	well	as	having	
resolution	of	respiratory	symptoms	were	regarded	as	PTB	negative.		
	
The	diabetes	case	definition:	
1)	Participant	is	known	to	have	DM	prior	to	enrolment;	
2)	Participant	is	on	oral	antiglycaemic	agents	and/or	insulin;		
Consecutive	adult	
patients	attending	
diabetes	clinic
Screened	for	PTB	by
GeneXpert	and	chest	
radiograph
Diagnosed	with	PTB
No	PTB	diagnosed
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3)	Participant	meets	the	biochemical	criteria	for	DM	diagnosis	as	defined	by	
the	American	Diabetes	Association(16)	namely	a	FBG	of	>7.0mmol/l,	2hBG	of	
>=11.1mmol/l	or	an	HbA1c	of	>6.5%.		
	
A.2.2.4	Inclusion	and	exclusion	Criteria			
	
All	male	and	female	patients	older	than	18	years	who	were	diagnosed	with	pulmonary	
TB	(PTB)	and	underwent	chest	radiography,	as	part	of	the	larger	study,	will	be	in	
included	in	this	study.		
Participants	who	were	diagnosed	with	PTB	but	did	not	have	a	chest	radiograph,	as	
well	as	those	who	refused	HIV	screening,	will	be	excluded	from	the	analysis.		
	
A.2.3	Measurement		
	
A.2.3.1	Research	procedures	
Written	informed	consent	(Appendix	D5)	will	be	obtained	from	all	participants	by	
clinical	research	workers	(CRW)	in	the	language	of	the	patient’s	choice.	All	consented	
participants	underwent	screening	for	DM	as	part	of	the	parent	study.	This	included	
phlebotomy	for	glycosylated	haemoglobin	(HbA1c),	fasting	blood	glucose	(FBG)	and	a	
two	hour	fasting	oral	glucose	tolerance	test	(2hBG).	The	2hBG	was	omitted	in	those	
participants	with	known	DM.		
	
A.2.3.2	Data	collection	
Basic	demographic	information	and	a	standardized	STEPs	chronic	disease	risk	factor	
tool	(Appendix	D3)	will	be	completed	by	a	clinical	research	worker	for	all	participants.	
HIV	status	will	also	be	recorded.		
	
Chest	radiographs	will	be	analyzed	using	a	standardized	tool	(Appendix	D4).	This	tool	
will	be	used	to	record	specific	radiographic	changes	related	to	pulmonary	TB,	and	
where	they	are	located:	parenchymal	abnormalities,	lung	field	opacifications,	hilar	
and	mediastinal	lymphadenopathy,	cardiothoracic	ratio,	pulmonary	effusion	and	
cavitation.	The	chest	radiograph	will	be	read	by	two	clinicians,	a	research	medical	
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officer	and	a	radiologist.	They	will	each	complete	the	reporting	tool	independently	
and	be	blinded	to	the	DM	and	HIV	status	of	the	participant.	If	there	is	discordance	
between	the	reports	the	chest	radiograph	will	be	read	a	third	time	by	a	physician	and	
consensus	reached.		
	
Variables	for	this	analysis	will	be	extracted	from	these	tools.	All	data	recorded	will	be	
anonymized	and	captured	on	an	Access	database.		
	
A.2.3.3	Sample	size	and	power	calculations	
The	most	common	atypical	feature	of	TBDM	on	chest	radiograph	is	lower	lobe	
involvement	which	occurs	in	between	50%	–	86%	for	TBDM	patients	and	20%	-	46%	
for	patients	with	TB	only	(17-19).	Using	the	upper	limits	of	this	prevalence	to	detect	a	
difference	at	alpha	=	0.05	and	80%	power,	37	TBDM	and	37	TB	only	cases	are	needed.	
In	this	sample,	we	have	21	TBDM	with	completed	chest	radiographs	and	84	non-DM	
TB.	Due	to	this	smaller	sample	the	power	decreases	to	78%	at	alpha	=	0.05.	This	
reduction	in	power	will	increase	the	probability	of	committing	a	Type	II	error,	
meaning	that	we	may	find	no	difference	in	radiographic	manifestations	of	pulmonary	
TB	between	TB	and	TBDM,	when	indeed	they	are	present.	The	analysis	of	the	
secondary	objective	may	also	be	underpowered	due	to	this	small	sample.	We	will	take	
this	into	consideration	when	undertaking	the	interpretation	of	results.		
	
A.2.3.4	Study	variables	
Study	variables	are	listed	in	table	1.	The	primary	outcomes	will	be	atypical	features	of	
tuberculosis	on	chest	radiograph	(lower	lobe	opacification	and	cavities).	Participant	
characteristics	include	demographic	data	as	well	as	clinical	information	on	DM	
(glycaemic	control	measured	by	HbA1c),	TB	sputum	results	and	HIV	status.	Smoking	
status	will	be	recorded	as	this	may	alter	the	features	on	chest	radiograph.		
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Table	A-1:	Study	Variables	
	
Variable	 Type	 Definition	 Categories	
Age	 Continuous	 Independent	 >18	
Sex	 Categorical	 Independent	 Male	
Female	
Smoking	 Categorical	 Independent	 Non	Smoker	(never	
smoked/	former	
smoker)	
Smoker	(current	
smoker)	
HIV	status	 Categorical	 Independent	 Negative	
Positive	
CD4	 Continuous	 Independent	 >20+	
Previous	TB	 Categorical	 Independent	 No		
Yes	
HbA1c	 Continuous	 Independent	 >2+	
Smear	status	 Categorical	 Independent	 Negative	
Scanty	
One	plus	
Two	plus	
Three	plus	
Not	done	
Genexpert	 Categorical	 Independent	 Negative	
Positive	
Indeterminate	
Not	done	
Sputum	culture	 Categorical	 Independent	 Negative	
Positive		
Not	done	
Chest	radiograph	features:	
	
Parenchymal	abnormalities	
	
Location	
	
	
Airspace	opacities	
Cavities	
	
Location	
	
	
	
Miliary	nodules	
	
	
Pleural	effusion	
	
	
Location	
	
	
Lymphadenopathy	
	
	
	
	
Categorical	
	
	
	
	
	
Categorical	
	
	
	
	
	
	
Categorical	
	
	
Categorical	
	
	
Categorical	
	
	
Categorical	
	
Dependent	 	
	
No	
Yes	
	
Left	
Right	
	
No	
Yes	
	
Left	
Right	
	
	
No	
Yes	
	
No	
Yes	
	
Left	
Right	
	
No	
Yes	
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Hilar	
	
	
Location	
	
	
Mediastinal	
	
	
																Location	
	
	
	
	
	
	
	
	
	
	
	
	
	
No	
Yes	
	
Left	
Right	
	
No	
Yes	
	
Left	
Right	
	
	
	
	
A.2.4	Statistical	analysis	plan	
	
A.2.4.1	Descriptive	analysis	
Participant	characteristics	will	be	described	using	means	and	standard	deviations	for	
normally	distributed	continuous	variables,	and	medians	and	inter-quartile	ranges	for	
non-parametric	continuous	variables.	Frequency	tables	with	proportions	will	be	used	
to	describe	categorical	variables.	These	characteristics	will	be	tabulated	and	stratified	
by	DM	status.	Chest	radiograph	features	also	be	described	with	simple	proportions,	
tabulated	and	stratified	by	DM	status.	A	third	exploration	will	include	stratification	of	
chest	radiograph	features	by	HIV	status.	For	the	DM	group,	features	on	chest	
radiograph	will	also	be	stratified	by	glycaemic	control	which	will	be	a	function	of	
HbA1c	level	according	to	the	American	Diabetes	Association(16).	We	chose	HbA1c	as	
a	measure	of	glycemic	control	as	it	has	been	shown	to	accurately	reflect	average	
glycemic	control	over	the	previous	8	–	12	weeks,	as	well	as	being	a	sensitive	measure	
of	diabetes	severity(20).	Differences	between	the	groups	will	be	determined	using	Chi	
squared	tests	and	Fisher’s	exact	test	for	categorical	data.	Significance	testing	will	be	
conducted	using	two	sided	p-values	and	95%	confidence	intervals.		
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A.2.4.2	Logistic	regression	
Univariate	and	multivariate	logistic	regression	will	be	used	to	describe	the	association	
between	individual	radiographic	characteristics	and	disease	status,	adjusting	for	a	
priori	factors	which	may	influence	the	outcome.	These	include	age	and	sex,	as	well	as	
smoking	status	and	history	of	previous	PTB	which	may	independently	change	the	
chest	radiograph	appearance.	Model	fit	will	be	assessed	using	likelihood	ratio	test	for	
nested	models	and	Akaike’s	Information	Criterion	(AIC)	for	non-nested	models.		
	
All	data	will	be	analyzed	using	STATA	13.1	(StataCorp,	College	Station,	TX,	USA).	
	
A.3	Ethical	considerations	
	
A.3.1	Harm	
There	will	be	minimal	risks	to	the	participants.	Phlebotomy	will	be	conducted	by	a	
trained	phlebotomist,	ensuring	that	there	is	minimal	pain	incurred	and	low	risk	of	soft	
tissue	injury	or	hematoma.	Chest	radiographs	are	safe	with	minimal	radiation	
exposure	as	according	to	the	United	Nations	Scientific	Committee	on	the	Effects	of	
Atomic	Radiation	a	single	chest	radiograph	exposes	the	patient	to	about	0.05	mSv,	
which	is	about	the	radiation	dose	people	are	exposed	to	naturally	over	the	course	of	
10	days.	
	
For	the	study	personnel	there	is	a	risk	of	needle	stick	injury.	This	risk	will	be	
minimized	by	proper	training	on	phlebotomy.	If	such	an	injury	does	occur	then	post-
exposure	prophylaxis,	in	the	form	of	anti-retrovirals,	and	appropriate	counselling	and	
follow	up	will	be	provided	for	the	staff	member.		
	
A.3.2	Autonomy	
During	the	informed	consent	procedure,	it	will	be	emphasized	to	the	participant	that	
the	choice	to	partake	in	the	study	is	entirely	at	their	own	discretion	and	that	their	
clinical	care	will	not	be	negatively	affected	if	they	choose	not	to	participate.	They	will	
also	be	provided	with	the	choice	to	withdraw	at	any	point.	
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A.3.3	Benefit	
Participants	will	be	screened	for	DM	which	is	not	part	of	routine	TB	care.	They	will	be	
referred	to	the	appropriate	facility	for	further	care	if	they	are	found	to	be	diabetic.	
Participants	will	be	compensated	with	R30	for	travel	expenses.		
	
A.3.4	Informed	consent	process	
Informed	consent	will	be	taken	by	a	trained	community	research	worker.	It	will	be	
conducted	in	the	language	most	familiar	to	the	participant.	The	nature	of	the	study,	
procedures,	risks,	benefits	and	option	to	withdraw	at	any	point	will	be	explained	to	
the	participant.	Informed	consent	documents	will	be	signed	by	both	the	CRW	and	the	
participant	and	dated.	For	those	participants	who	cannot	sign,	a	thumb	print	will	be	
taken.	A	copy	of	the	informed	consent	document	will	be	given	to	the	participant	to	
keep.		
	
A.3.5	Privacy	and	confidentiality	
Data	collected	is	of	a	sensitive	nature	therefore	privacy	and	confidentiality	is	of	
utmost	importance.	We	will	ensure	that	all	data	collected	will	kept	confidential	by	
undertaking	the	following	measures:		
1)	The	participant’s	name	with	not	be	linked	to	the	case	report	form	(CRF)	and	
each	participant	will	be	issued	with	a	unique	participant	identification	number	
and	chest	radiographs	and	samples	will	be	labelled	with	this	number;	
2)	all	interviews	and	procedures	will	be	conducted	in	a	private	space;		
3)	CRFs	will	be	kept	onsite	in	a	locked	filing	cabinet	with	access	only	to	the	
necessary	study	personnel.		
	
A.4	Dissemination	of	results	
	
Currently	there	are	no	clear	screening	guidelines	to	screen	persons	with	DM	for	TB.	This	
study	will	contribute	to	the	diagnosis	of	TB	in	persons	with	diabetes	and	interpretation	of	
ambiguous	chest	radiographs	in	persons	with	diabetes.	The	results	will	be	written	up	and	
disseminated	to	the	clinicians	at	Ubuntu	TB	clinic.	We	will	also	disseminate	nationally	and	
internationally	through	academic	meetings	and	publication	in	a	peer-reviewed	journal.			
	 12	
	
A.5	Logistics	
	
A.5.1	Timeline	
Participants	were	recruited	between	July	2013	and	October	2015,	as	part	of	the	
parent	TB	and	DM	study.	Data	collection	was	completed	in	September	2015.		
	
A.5.2	Budget	
The	parent	study	was	funded	by	a	Wellcome	Trust	Strategic	Funding	Clinical	
Infectious	Disease	Research	Initiative	Fellowship	to	Dr	Oni	(Fund	number:	412300).	
No	additional	funding	is	needed	for	this	study.	
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Part	B:	Literature	Review	
	
B.1	Introduction	
	
Tuberculosis	(TB)	is	an	ancient	disease,	which	has	afflicted	humanity	for	centuries.	With	the	
advent	of	contemporary	public	health	measures	and	the	discovery	of	effective	chemotherapy	
in	the	mid	20th	Century,	TB	became	a	treatable	disease	and	incidence	declined(1).	However,	
TB	rates	in	the	1990’s	began	to	climb	again	fueled	by	the	Acquired	Immune	Deficiency	
Syndrome	(AIDS)	epidemic,	especially	in	Sub-Saharan	Africa(2).	In	2015,	10.4	million	people	
fell	ill	with	TB	globally(3),	ranking	TB	as	a	leading	cause	of	death	worldwide,	alongside	Human	
Immunodeficiency	Virus	(HIV)(3).		
	
TB	has	been	highlighted	by	the	United	Nations	under	their	Sustainable	Development	Goals	
(SDG)	–	under	SDG	3:	“Ensure	healthy	lives	and	promote	well-being	for	all	ages”(4).	Included	
in	this	goal	is	the	ending	of	the	TB	epidemic	by	2030.	Within	the	End	TB	strategy,	the	World	
Health	Organization	(WHO)	aims	to	reduce	TB	deaths	by	95%	in	2035	(compared	with	2015)	
and	reduce	the	incidence	rate	to	<10/100	000(5).	These	are	ambitious	targets,	which	can	
only	be	achieved	through	multi-sector	collaboration.		
	
Major	strides	have	been	made	in	TB	control	over	the	past	two	decades	with	a	drastic	decline	
in	the	mortality	and	incidence	of	TB,	especially	in	the	developed	world(3).	Unfortunately,	
approximately	4.3	million	TB	cases	are	missed	by	health	care	systems	annually(3).	Additional	
interventions,	as	well	as	improved	implementation	of	existing	programs,	targeting	
populations	who	are	vulnerable	and	at	high	risk	of	developing	TB	are	needed.	These	
populations	include	those	who	are	living	with	HIV,	prisoners,	miners,	the	homeless,	children	
and	other	clinical	risk	groups,	such	as	those	living	diabetes	(DM)(6).		
	
Due	to	the	epidemiological	transition	there	is	a	changing	burden	of	disease	in	the	developing	
world.	Non-communicable	diseases	(NCDs)	now	contribute	to	50%	of	the	morbidity	in	Sub-
Saharan	Africa(7),	where	HIV	and	TB	is	most	prevalent.	This	increase	in	NCDs	is	due	to	rapid	
urbanization,	accompanied	by	decrease	in	physical	activity	and	the	increase	in	consumption	
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of	processed	food	and	related	obesity(8).	South	Africa	has	not	been	excluded	from	this	NCD	
epidemic.	NCDs	make	up	four	of	the	top	10	causes	of	death	with	diabetes	moving	from	tenth	
to	sixth	position	between	1997	and	2012(9).	This	changing	burden	of	disease	emphasizes	the	
importance	in	understanding	the	interactions	between	NCDs	and	prevalent	communicable	
diseases,	in	order	to	prevent	disease	spread	and	control	disease	burden.	
	
B.1.1	Populations	at	risk	
	
Both	HIV	and	DM	are	well-recognized	risk	factors	for	developing	TB.	South	Africa	has	the	
largest	HIV	epidemic	worldwide	with	approximately	7	million	people	living	with	HIV	and	a	
population	prevalence	of	19.2%(10).	People	living	with	HIV	are	26	times	more	likely	to	
develop	TB	than	those	who	are	uninfected(3).	TB	incidence	declines	with	the	administration	
of	ART	but	TB	risk	remains	high(11).	The	adult	DM	prevalence	in	South	Africa	has	been	
estimated	at	7%(12)	and	due	to	the	epidemiological	transition	this	prevalence	is	set	to	
increase.	In	South	Africa,	glycaemic	levels	in	persons	with	diabetes	are	often	poorly	
controlled(13),	potentially	increasing	their	risk	of	developing	TB.		A	recent	systematic	review	
found	that	those	living	with	DM	have	as	much	as	three	times	greater	risk	of	developing	
TB(14).	This	review	had	limited	data	on	TB	risk	in	Africa,	where	TB	burden	is	highest	with	
studies	conducted	in	Africa	since	this	review	was	published	confirming	this	risk(15).	The	
estimated	proportion	of	TB	due	to	DM	in	2030	will	be	12.6%	(95%	CI	9.2-	17.3%)(16)	and	a	
recent	study	conducted	in	Khayelitsha	estimated	that	the	population	attributable	risk	of	TB	
due	to	DM	in	this	population	was	14%	(Oni	et	al,	in	press).	Worryingly,	a	large	percentage	of	
DM	in	TB	patients	is	undiagnosed(17,	18).	While	both	HIV	and	DM	are	individually	prevalent	
in	South	Africa,	there	is	the	potential	for	increasing	co-prevalence	as	the	HIV-infected	
population	ages.			
		
B.1.2	The	utility	of	the	chest	radiograph	in	the	diagnosis	of	TB	
	
Early	detection	and	treatment	of	TB	is	one	of	the	pillars	of	the	WHO	End-TB	strategy(5).	
Delayed	diagnosis	results	in	increased	morbidity,	mortality	and	transmission	of	TB(19-21).	To	
aid	rapid	diagnosis	it	is	essential	to	understand	the	clinical	and	radiographic	presentation	of	
TB,	and	how	common	comorbidities	influence	this	presentation,	as	atypical	presentations	
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may	result	in	delayed	diagnosis(21,	22).	Chest	radiographs	have	been	a	part	of	screening	and	
diagnosis	of	TB	since	the	early	20th	century(23).	The	chest	radiograph	has	been	found	to	be	
highly	sensitive	in	detecting	TB	but	it’s	specificity	is	low(24).	Modern	technologies	such	as	
GeneXpert	molecular	diagnosis	have	revolutionized	the	diagnosis	of	TB	but	chest	radiography	
still	plays	an	important	role.	Chest	radiographs	remain	essential	in	targeted	high	risk	
population	screening(6)	and	in	the	diagnostic	algorithm	for	smear	negative	TB(25,	26).	Chest	
radiography	is	still	a	cost	effective	modality	in	low	resource	regions	where	GeneXpert	may	
not	be	freely	available(24).			
	
The	reliability	of	chest	radiography	as	a	TB	diagnostic	tool	is	reduced	by	inter-reader	
variability	and	radiographic	presentations	depends	on	underlying	immune	status	and	other	
co-morbidities.	To	address	this,	in	2005,	the	chest	radiographic	reading	and	reporting	system	
(CRRS)	was	developed	in	Cape	Town,	with	the	aim	of	decreasing	inter-observer	discrepancies	
in	chest	radiograph	reading	and	reporting	for	epidemiological	studies(27).	The	reliability	of	
this	tool	in	diagnosing	culture	positive	TB	with	typical	radiographic	manifestations	has	been	
validated	in	a	the	clinical	setting(28).	The	limitation	of	this	tool	is	that	sensitivity	and	
specificity	declines	when	radiographic	presentation	of	TB	is	atypical,	such	as	in	HIV-infected	
patients(28).		
	
B.1.3	Typical	radiographic	features	of	TB		
		
TB	in	adults	classically	presents	in	one	of	two	ways	on	chest	radiograph.	Most	common	is	the	
post	primary	pattern,	which	includes	apical	infiltrates	and/or	cavities	in	the	upper	lobes	or	
infiltrates	in	the	apical	segments	of	the	middle/lower	lobes.	Less	common	is	the	primary	
(atypical)	pattern,	presenting	with	atypical	features	on	chest	radiograph	such	as	hilar	and/or	
mediastinal	adenopathy,	diffuse	reticulonodular	infiltrate,	as	well	as	infiltrates	and	cavities	of	
the	lower/middle	lobes	or	normal	radiographs.	Other	patterns	of	presentation	on	chest	
radiograph	include	miliary	pattern	and	pleural	effusions(29).			
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B.2	Objectives	
	
The	primary	objective	of	this	literature	review	was	to	identify	literature	describing	the	chest	
radiographic	manifestations	of	pulmonary	tuberculosis	in	adult	patients	with	drug	sensitive	
or	resistant	tuberculosis	and	comorbid	i)	DM,	ii)	HIV	and	iii)	DM	and	HIV.		
	
The	secondary	objectives	were	to	a)	identify	other	parameters	which	may	influence	
radiographic	presentation	in	this	population,	and	b)	identify	the	most	common	atypical	
radiographic	features	within	each	group.		
	
B.3	Methods	
	
B.3.1	Search	strategy	
	
The	Pubmed	online	database	was	used	to	search	for	relevant	original	studies	and	reviews.	
We	searched	using	the	following	terms:	“tuberculosis”,	“diabetes	mellitus	or	diabetes”,	
“radiograph*”,	“chest	x-ray”,	“HIV	or	human	immunodeficiency	virus”.	Combinations	of	the	
terms	were	used	to	find	literature	specific	for:	
I. Features	of	TBDM	chest	radiography	
II. Features	of	tuberculosis	and	HIV	(TBHIV)	chest	radiography		
	
The	bibliographies	of	relevant	literature	were	also	reviewed	for	possible	studies	to	include	in	
the	literature	review.		
	
B.3.2	Inclusion	criteria	
	
All	studies	included	were	published	in	English.	Studies	were	conducted	on	adult	participants	
with	a	confirmed	microbiological	diagnosis	of	pulmonary	tuberculosis.	Definitions	of	
tuberculosis,	HIV	and	diabetes	diagnosis	needed	to	be	provided.	Outcomes	needed	to	include	
analysis	or	description	of	chest	radiograph	features	of	pulmonary	tuberculosis.	Both	
descriptive	and	analytical	studies	were	included.	Literature	that	was	accessible	through	the	
University	of	Cape	Town	(UCT)	Library	was	included.		
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B.3.3	Exclusion	criteria	
	
Studies	conducted	on	minors	and	that	were	not	published	in	English	were	excluded.		
	
B.3.4	Study	Assessment	
	
Studies	were	critically	reviewed	and	assessed	according	to	the	study	design	presented	and	
methodology.	Limitations	and	potential	areas	of	bias	and	confounding	were	assessed	for	
each	study	and	considered	when	discussing	the	literature.		
	
B.4	Results	
	
For	the	TBDM	related	search	our	search	strategy	identified	303	articles.	Of	these	21	met	our	
inclusion	criteria.	An	additional	2	studies	were	identified	from	the	bibliographies	of	articles	
included	in	the	review.		
	
For	the	TBHIV	related	search,	our	search	strategy	identified	596	articles.	Of	these	40	met	our	
inclusion	criteria.	21	studies	were	not	accessible	through	UCT	libraries.		
	
B.4.1	Radiographic	features	of	TB	in	HIV-infected	patients	(TBHIV)	
The	literature	divides	the	chest	radiograph	presentation	of	TB	by	typical	(post	primary)	and	
atypical	(primary)	patterns,	as	well	as	individual	features.	Table	B-1	lists	the	atypical	features	
that	each	study	found	to	be	associated	with	HIV-infection.	Cavitation	was	the	most	frequent	
presentation	of	pulmonary	TB,	irrespective	of	HIV	infection	(28-30,	32,	34,	37)	with	a	
prevalence	ranging	from	13%(30)	–	70.8%(31)	in	HIV	infected	patients,	and	38,8%(32)	–	
91,5%(31)	in	uninfected	patients.	All	of	the	literature	found	that	HIV-infected	patients	were	
more	likely	to	have	an	atypical	chest	radiograph	presentation(30-42).	Table	B-1	summarizes	
the	literature	found,	which	describes	the	radiographic	differences	between	HIV-infected	and	
uninfected	patients	with	pulmonary	TB.	The	literature	found	HIV-infected	patients	were	
more	likely	to	have	the	following	atypical	features:	adenopathy(30,	31,	33-35,	37,	38,	40,	42),	
middle/lower	lobe	infiltrates(35,	36,	39,	41),	lobar	consolidation(31,	37,	38)	and	lack	of	
cavities(30-38,	40,	41).	HIV-infected	and	non-infected	patients	had	similar	a	predisposition	
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for	pleural	effusions	and	miliary	pattern	(30-34,	36,	38-40).	The	prevalence	of	these	features	
amongst	HIV-infected	patients	varied	in	the	literature	as	follows:		adenopathy	20,4%(31)–	
31,1%(34),	middle/lower	lobe	infiltrates	19%(35)	–	48,8%(41),	lobar	consolidation	10%(37)	–	
42%(30),	pleural	effusions	11%(33)–	43%(34)	and	military	pattern	6%(38)	–	34,2%(32).			
	
Three	studies	consolidated	the	atypical	features	into	a	count	of	overall	atypical	chest	
radiograph(31,	33,	39).	The	prevalence	of	having	an	overall	atypical	chest	radiograph	ranged	
from	14,2%(31)	–	37,3%(33)	in	HIV-infected	patients,	and	0%(31)	-23%(39)	in	HIV-uninfected	
patients.	The	only	other	risk	factors	which	were	also	associated	with	HIV-infection	in	these	
studies	were	a	lower	level	of	sputum	smear	positivity(39)	and	lower	tuberculin	skin	test	
positivity(33);	a	higher	prevalence	of	drug	use(31).	
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Table	B-1:	Summary	of	Studies	Comparing	Chest	Radiograph	Features	of	TB	in	HIV-infected	and	HIV	uninfected	Patients		
	
AUTHOR	 YEAR	OF	
PUBLICATION	
STUDY	
DESIGN	
CITY,	
COUNTRY	
STUDY	
SETTING	
SAMPLE	SIZE	
(HIV+/HIV-)	
HIV+	MORE	
LIKELY	TO	HAVE	
ATYPICAL/	
PRIMARY	
FEATURES	ON	
CXR	(YES/NO)*	
HIV+	
PREDOMINANT	
RADIOGRAPH	
FEATURES	
FEATURES	
ASSOCIATED	WITH	
IMMUNOSUPRESSION	
LONG	ET	AL(33)	 1991	 Cross-
sectional	
Haiti	 Hospital	 67/158	 Yes	 Adenopathy,	Normal	
Radiograph	
AIDS	presents	more	
frequently	with	primary/	
atypical	disease	
pattern***		
BATUNGWANAYO	
ET	AL(34)	
1992	 Cross-
sectional		
Kigali,	Rwanda	 Hospital	 48/11	 Yes	 Adenopathy,		Pleural	
Effusion	
-	
POZNIAK	ET	AL(35)	 1995	 Cross-
sectional	
Harare,	
Zimbabwe	
TB	Unit,	City	
Health	
Department	
202/220	 Yes	 Adenopathy,		Pleural	
Effusion,	Fewer	
Cavities	
-	
MLIKA-CABANNE	
ET	AL(36)	
1995	 Cross-
sectional	
Tanzania	and	
Burundi	
Hospital	 185/119	 Yes	 Adenopathy,	
Consolidation,	
Nodular	Pattern,	
Fewer	Cavities	
-	
TSHIBWABWA		
ET	AL(37)	
1997	 Case	control	 Zaire	and	
Zambia	
Hospital	 963/1000	 Yes	 Adenopathy,	Pleural	
Effusion,	Interstitial	
Pattern,	Miliary	
Pattern,	Lobar	
Consolidation	
-	
AWIL	ET	AL(38)	 1997	 Cross-
sectional	
Gulu	District,	
Uganda	
Hospital,	In-	
and	Out-	
Patient	
92/61	 Yes	 Adenopathy,		
Lobar	Consolidation	
-	
JOHNSON	ET	
AL(39)	
1997	 Nested	
cross-
sectional	
Kampala,	
Uganda	
Hospital	 212/111	 Yes**		 Lower	Lung	Field	
Infiltrate	
-	
DE	ALBUQUERQUE	
ET	AL(40)	
2001	 Cross-
sectional	
Pernambuco,	
Brazil	
Hospital	
Outpatient	
39/236	 Yes	 Miliary	Pattern,	
Adenopathy,	Pleural	
Effusion*		
-	
ADERAYE	ET	AL(41)	 2004	 Cross-
sectional	
Addis	Ababa,	
Ethiopia	
Hospital	
Outpatient	
94/69	 Yes	 Miliary	Pattern,	
Interstitial	Infiltrate,		
Pleural	Effusion	
-	
	 22	
PICON	ET	AL(31)	 2007	 Cross-
sectional	
Porto	Alegre,	
Brazil	
Hospital	 113/118	 Yes	 Multifocal	Disease,	
Adenopathy	
-	
CHAMIE	ET	AL(42)	 2010	 Cross-
sectional		
Kampala,	
Uganda	
TB	Referral	
Centre	
873/1141		 Yes	 Normal	Radiograph,		
Miliary	Pattern,	
Adenopathy,	Pleural	
Effusion	
CD4	<150	more	likely	to	
have	normal	radiograph,	
miliary	pattern,	
adenopathy	and	pleural	
effusion	
ANGTHONG,	
ANGTHONG(32)	
2011	 Cohort	 Nakon	Nayok,	
Thailand	
Hospital	 38/139	
(CD4	>200:	5;	
CD4	<200:	33)	
Yes	 Diffuse	Nodular	
Opacities,		
Miliary	Pattern	
CD4	>200	more	likely	to	
have	cavitation,	mass	
lesion.	CD4	<	200	more	
likely	to	have	diffuse	
nodular	opacities,	
miliary	pattern	
KISEMBO	ET	AL(30)	 2012	 Cross-
sectional	
Kampala,	
Uganda	
Hospital	 186/27		
(CD4	>50:	80;	
CD4	<50:	102)	
Yes	 Miliary	Pattern,		
Adenopathy	
CD4	>	50:	more	
consolidation,	more	
cavities	CD4	<50:	more	
adenopathy	
*	Proportion	of	HIV	infected	participants	with	an	atypical	feature	of	tuberculosis	on	chest	radiograph	was	greater	than	in	HIV	uninfected	participants.	
**Not	statistically	significant	
***This	study	did	not	use	the	CD4	cell	count	as	a	measure	of	immunosuppression	and	stratified	participants	according	to	clinical	AIDS	status.	
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B.4.2	Radiographic	features	of	TB	in	patients	with	Diabetes	(TBDM)	
	
Table	B-2	summarizes	the	literature	found	describing	the	radiographic	features	of	PTB	in	
patients	with	diabetes.	The	most	commonly	reported	findings	on	chest	radiograph	were	the	
presence	and	location	of	lobar	opacifications/lesions	and	cavities.	Overall	there	was	some	
variation	in	the	findings	in	the	literature	with	regards	to	the	chest	radiograph	presentation	of	
TB	in	patients	with	DM,	however	the	majority	of	the	literature	found	that	TBDM	patients	had	
a	predominance	of	lower	lung	field	involvement	and	more	frequent	cavitation.		Seventeen	
studies	reported	on	location	of	opacifications/lesions	related	to	TB.	Of	these,	twelve	found	a	
predominance	of	lower	lung	field	involvement	in	TBDM	patients(43-54),	with	a	prevalence	
ranging	between	15,2%(50)–	29%(47).	Of	the	eighteen	studies	that	reported	on	the	presence	
of	cavitation,	twelve	studies	found	that	TBDM	patients	have	more	frequent	cavitation	than	
non-TBDM	patients(45,	47,	48,	50,	51,	53-59),	with	a	prevalence	of	19,2%(55)	–	50,8%(60).		
	
A	few	studies	commented	on	other	chest	radiograph	features	of	TB.	Here,	findings	varied	
substantially.	Jabbar(49)	found	that	32%	of	the	diabetics	in	his	sample	had	pleural	effusions	
but	he	had	no	control	group,	whereas	Tatar(56)	found	that	TBDM	patients	were	more	likely	
to	have	pleural	effusions.	Both	Wang(50)	and	Alavi(57)	contradict	this	and	found	no	
association	between	TBDM	and	the	presence	of	pleural	effusion	on	chest	radiograph.	
Wang(50)	did	find	that	TBDM	was	associated	with	more	consolidation,	with	Alavi(57)	finding	
more	frequent	miliary	patterning	in	TBDM	patients.			
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Table	B-2:	Summary	of	Studies	Comparing	Chest	Radiograph	Features	of	TB	in	Patients	with	and	without	Diabetes		
	
AUTHOR	 YEAR	OF	
PUBLICATION	
STUDY	DESIGN	 CITY,	COUNTRY	 STUDY	SETTING	 PREVALENCE	OF	
DIABETES	IN	TB	
CASES	
PREDOMINANCE	OF	
LOWER	LUNG	FIELD	
INVOLVEMENT	
MORE	LIKELY	
TO	HAVE	
CAVITATION	
WEAVER(43)		 1974	 Cross	sectional		 Atlanta,	Usa		 TB	Hospital	 11%	(23/205)	 Yes	 -	
MARAIS(44)		 1980	 Cross	sectional	 Pelonomi,	South	
Africa	
Pelonomi	Hospital	 2.1%	(9/436)	 Yes	 -	
JAIN	ET	AL(61)		 1985	 Cross	sectional	 Jaipur,	India	 Hospital	 6.9%	(16/230)	 No	 No	
MORRIS	ET	AL(46)		 1992	 Case	Control		 San	Antonio,	Usa	 Chest	Hospital	 		 Yes	 No	
UMUT	ET	AL(45)	 1994	 Case	Control	 Istanbul,	Turkey	 Unclear	–	Possibly	
Hospital	
		 Yes	 Yes	
AL-WABEL	ET	
AL(62)	
1997	 Case	Control		 Abha,	Saudi	Arabia	 Hospital		 		 No	 No	
PEREZ-GUZMAN	ET	
AL(47)	
2001	 Case	Control	 Mexico	City,	Mexico	 Chest	Hospital	 		 Yes	 Yes	
SHAIKH	ET	AL(48)	 2003	 Cross	sectional	 Riyadh,	Saudi	Arabia	 Chest	Hospital	 27%	(187/692)	 Yes	 Yes	
	WANG	ET	AL(55)	 2005	 Cross	sectional	 Taiwan	 Tertiary	Care	Referral	
Centre	
21.5%	(99/461)	 No	 Yes	
	JABBAR	ET	AL(49)	 2006	 Case	Control		 Karachi,	Pakistan	 Tertiary	Hospital		 	 Yes	 -	
TATAR	ET	AL(56)	 2009	 Case	Control	 Izmir,	Turkey	 TB	Hospital	 7.3%	(78/1063)	 -	 Yes	
WANG	ET	AL(50)	 2009	 Cross	sectional	 Kaohsiung,	Taiwan	 Tertiary	Hospital	
With	Primary	Care	
Component		
34%	(74/217)	 Yes	 Yes	
OZSAHIN	ET	AL(63)	 2011	 Cross	sectional	 Kastamonu,	Turkey	 TB	Hospital	–	Males	
Only	
10.1%	(81/800)	 -	 No	
CARREIRA	ET	
AL(51)	
2012	 Case	Control		 Lisbon,	Portugal	 Respiratory	Hospital	 		 Yes	 Yes	
ALAVI	ET	AL(57)	 2014	 Cross	sectional	 Iran	 TB	Referral	Hospital		 24%	(36/149)	 -	 Yes	
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SINGH	ET	AL(52)	 2015	 Cross	sectional	 India	 Tertiary	Care		 		 Yes	 -	
MORENA-
MARTINEZ	ET	
AL(58)	
2015	 Cross	sectional	 Barcelona,	Spain	 All	Patients	On	
Program	For	
Prevention	And	
Control	Of	TB	In	
Barcelona		
5.9%	(349/5849)	 -	 Yes	
GIL-SANTANA	ET	
AL(64)	
2016	 Case	Control		 Brazil	 Primary	Care		 		 No	 No	
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B.4.3	Radiographic	features	of	TB	in	patients	with	diabetes	and	HIV	(TBDMHIV)	
	
There	was	a	paucity	of	literature	describing	radiological	features	of	TB	in	patients	with	both	
DM	and	HIV	(TBDMHIV).	Only	one	of	the	studies	describing	features	of	TB	in	HIV	patients	
included	recording	DM	status	within	the	methods,	and	this	was	retrospectively	retrieved	
from	case	records,	however	the	results	did	not	report	DM	prevalence	in	this	cohort(31).	Of	
the	TBDM	literature,	nine	studies	mentioned	HIV	status.	Of	these,	eight	were	retrospective	
record	reviews.	Four	of	these	studies	reported	zero	HIV-infected	DM	patients(46,	47,	50,	53)	
and	three	excluded	HIV-infected	patients	from	their	sample(51,	57,	59).	One	study,	
conducted	in	Brazil,	reported	98%	of	TBDM	patients	were	tested	for	HIV	with	zero	testing	
positive(64).		
	
B.4.4	Additional	variables	influencing	radiographic	features	of	TB	on	chest	radiograph	
	
The	literature	search	identified	four	additional	variables	that	may	alter	the	appearance	of	TB	
on	chest	radiograph.	These	were	age,	glycemic	control,	degree	of	immunosuppression	and	
smear	status.		
	
The	effect	of	age	and	glycemic	status	is	summarized	in	Table	B-3.	We	found	two	studies	that	
investigated	the	association	between	glycaemic	control	in	TBDM	patients	and	radiographic	
manifestations	of	pulmonary	TB.	Both	these	studies	showed	that	TBDM	patients	with	good	
glycemic	control	(defined	as	an	HbA1c	<7.0%)	had	more	normal	radiographic	
presentations(54,	59).		
	
Age	has	also	been	shown	to	modify	the	chest	radiographic	presentation	of	TB.	Al-Tawfiq(65)	
found	that	older	patients	(>60	years)	with	TB	presented	with	fewer	cavities	and	more	
frequent	mid-	and	lower	zone	lesions.	This	is	similar	to	Chiang’s(54)	finding	in	2014.	Contrary	
to	this	finding,	when	stratifying	by	DM	status,	Perez-Guzman(53)	found	that	older	(>50	years)	
TBDM	patients	had	a	higher	frequency	of	cavitation	than	their	non-DM	counterparts.	They	
also	found	that	lower	lobe	lesions	increased	with	age	for	both	TB	and	TBDM	but	more	so	with	
TBDM(53).	
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Table	B-3:	Summary	of	Studies	Describing	Effect	of	Age	and	Glycemic	Control	on	
Radiographic	Presentation		
	
AUTHOR	 YEAR	OF	
PUBLICATION	
STUDY	
DESIGN	
CITY,	
COUNTRY	
STUDY	
SETTING	
EFFECT	OF	AGE	
ON	
RADIOGRAPHIC	
PRESENTATION	
EFFECT	OF	GLYCEMIC	
CONTROL	ON	
RADIOGRAPHIC	
PRESENTATION	
PEREZ-GUZMAN	
ET	AL(53)	
2000	 Case	
Control	
Mexico	
City,	
Mexico	
Respiratory	
Hospital	
Increase	prevalence	
of	lower	lobe	
lesions	for	both	
TBDM	and	TB.	
TBDM	have	a	higher	
prevalence	of	
cavitation	at	an	
older	age.		
-	
AL-TAWFIQ	ET	
AL(65)	
2009	 Cross-
Sectional		
Dhahran,	
Saudi	
Arabia	
Saudi	
Aramco	
Medical	
Services	
Organization	
>60	years	old	had	
fewer	cavities	
-	
PARK	ET	AL(59)	 2012	 Cross	
Sectional		
Seoul,	
South	
Korea	
Hospital	
Patients	
-	 Uncontrolled	DM	had	more	
frequent	cavities	than	non-
DM		
CHIANG	ET	
AL(54)	
2014	 Case	
Control		
Multiple	
Sites,	
Taiwan	
Tertiary	
Hospital	
>65	had	higher	
prevalence	of	lower	
lung	field	opacity	&	
fewer	cavities	(DM	
And	Non-	DM)	
Where	controlled	TBDM	had	
no	increased	risk,	
uncontrolled	DM	had	2.32	
(95%	CI	1.36	-	3.98)	times	
greater	risk	of	lower	lung	
field	opacities	and 1.84	(95%	
CI	1.20–2.84)	times	greater	
risk	of	cavitation	as	
compared	to	non-DM	TB	
patients.		
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The	degree	of	immunosuppression	also	appears	to	have	an	effect	on	chest	radiograph	
features	of	TB.	Presence	of	AIDS	and	CD4	count	were	used	as	a	marker	of	
immunosuppression	in	much	of	the	TBHIV	literature.	The	effect	of	CD4	count	is	summarized	
in	Table	B-1	and	Table	B-4.		
	
Long(33)	found	that	there	were	no	differences	between	HIV-infected	patients	with	and	
without	AIDS.	This	finding	could	be	due	to	the	small	sample	size	of	AIDS	patients	(10/225)	
entered	into	the	study.	By	contrast,	Batungwanayo(34)	found	that	AIDS	patients	had	more	
adenopathy	and	less	cavitation.	This	study	had	a	higher	proportion	of	AIDS	participants	(73%	
of	the	HIV-infected	cohort,	59%	of	the	total	sample).	In	these	studies,	there	is	a	risk	of	
misclassification	of	AIDS	status	as	participants	were	classified	using	a	clinical	syndrome	rather	
than	a	measurable	biological	marker,	such	as	CD4	count.	This	may	have	contributed	to	the	
varied	findings.			
	
Later	literature	used	the	CD4	count	as	measure	of	immune	status.	These	studies	found	that	
chest	radiographs	of	those	patients	with	a	CD4	count	of	<200	cells/mm3	had	more	atypical	
features	(or	features	of	primary	TB	infection)	than	those	participants	with	a	better	preserved	
immune	system(30,	32,	33,	42,	66-70).	Keiper(67)	found	that	while	a	lower	CD4	count	was	
significantly	associated	with	a	more	atypical	pattern,	the	CD4	count	for	the	typical	chest	
radiographic	TB	pattern	had	a	wider	range	(1-	990	vs	4	–	50).	A	study	conducted	in	South	
Africa	found	that	adenopathy,	normal	radiograph,	reticulo-nodular	pattern	and	lower-	or	
mid-zone	infiltrate	had	high	specificities	(76	–	100%)	for	CD4	<200	cells/mm3	(66).		
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Table	B-4:	Summary	of	Studies	Describing	Immune	Status	on	Radiographic	Presentation		
	
AUTHOR	 YEAR	OF	
PUBLICATION	
STUDY	
DESIGN	
CITY,	
COUNTRY	
STUDY	
SETTING	
SAMPLE	
SIZE	(CD4	
>200	
CELLS/MM3	
/CD4	<200	
CELLS/MM3)	
EFFECT	OF	CD4	
COUNT	
POST	ET	AL(66)	 1995	 Case	Control	 Cape	Town,	
South	Africa	
Hospital	 150*	 CD4	<	200:	adenopathy,	
diffuse	reticulonodular	
pattern,	miliary	pattern			
CD4>200:	Upper	zone	
infiltrates	
KEIPER	ET	
AL(67)	
1995	 Cross-
Sectional	
Philedelphia,	
United	
States	
Hospital	 11	/	26	 CD4	<200:	atypical	
pattern		
CD4	>200:	typical	
pattern	
ASIMOS	ET	
AL(68)	
1995	 Cross-
Sectional	
Charlotte,	
United	
States	
Hospital	 7	/	16	 CD4	<	200:	atypical	
pattern		
CD4	>200:	typical	
pattern	
PERLMAN	ET	
AL(71)	
1997	 Nested	Cross	
Sectional	
US	
Multicentre	
		 30	/	98	 CD4	<	200	had	more	
adenopathy	
ENG	SAN,	
MUHAMAD(69)	
2000	 Cross-
Sectional	
Kota	Bharu,	
Malaysia	
Hospital	 62	/	18	 CD4	<200	more	atypical	
pattern	
BUSI	RIZZI	ET	
AL(72)	
2003	 Retrospective	
Cross	
Sectional		
Italy	 Hospital	 50	/	159	 Higher	CD4	(on	HAART)	
had	post	primary/typical	
pattern	
DA	SILVA	ET	
AL(73)	
2006	 Cross-
Sectional	
Florianopolis,	
Brazil	
Hospital	 87*	 CD4	<200	had	more	
adenopathy	
GARCIA	ET	
AL(70)	
2007	 Cross-
Sectional	
Brazil	 Hospital		 11	/	27	 CD4	<200:	primary	
pattern		
CD4	>200:	post	primary	
pattern	
*No	further	details	given		
	
	
Two	studies	assessed	the	association	between	sputum	status	and	chest	radiograph	
appearance.	Both	Al	Tawfiq(65)	and	Ozsahin(63)	found	that	positive	sputum	smears	and	
cultures	were	associated	with	cavitation	on	chest	radiograph.	In	addition	to	this	Al	Tawfiq(65)	
also	noted	that	positive	smears	were	associated	with	upper	lobe	infiltrates.			
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B.5.	Discussion	
	
B.5.1	TBHIV	and	TBDM	alter	the	radiographic	manifestations	of	PTB		
This	review	reveals	that	both	TBHIV	and	TBDM	patients	have	unique	TB	presentations	on	
chest	radiograph.	TBHIV	patients	typically	have	an	atypical	or	primary	infection	presentation	
(which	includes	lower	lung	field	involvement),	with	TBDM	patients	more	likely	to	have	lower	
lung	field	lesions	and	increased	cavitation.	While	pleural	effusions	and	miliary	patterning	
were	similarly	distributed	in	HIV-infected	and	uninfected	patients,	the	literature	varied	in	this	
regard	when	comparing	TBDM	patients	to	non-DM	TB	patients.		
	
Much	of	the	TBDM	literature	did	not	account	for	HIV	status.	Apart	from	one	study	(which	
found	zero	HIV	infection	in	the	TBDM	cohort)	HIV	status	was	either	not	mentioned,	excluded,	
or	not	actively	screened	for	(mostly	due	to	the	retrospective	nature	of	the	studies).	As	
discussed	earlier,	with	rising	DM	prevalence	in	high	HIV	and	TB	burden	settings,	we	would	
expect	a	fair	proportion	of	TB	patients	to	have	both	HIV	and	DM.	We	would	therefore	expect	
that	patients	with	TB,	DM	and	HIV	would	also	have	an	atypical	radiographic	presentation,	the	
pattern	of	which	may	be	unique	to	this	population.	This	omission	may	account	for	some	of	
the	conflicting	findings	in	the	TBDM	literature	biasing	the	results.		
	
B.5.2	Relevance	of	individual	patient	characteristics	for	the	clinical	interpretation	of	TB	chest	
radiography	
	
Studies	by	Batungwanayo(34),	Mlika-Cabanne(36)	and	Aderaye(41)	found	that	even	though	
HIV-infected	patients	with	TB	often	present	atypically,	the	most	common	features	of	TB	on	
chest	radiograph	in	HIV-infected	participants	were	similar	to	those	in	HIV-uninfected	
participants	–	those	being	cavitation,	upper	lobe	infiltrates	and	parenchymal	opacifications.	
This	suggests	that	other	factors	may	modify	the	features	found	on	chest	radiography	of	HIV-
infected	TB	patients.		
	
Chest	radiography	is	used	for	both	screening	and	diagnosis	of	TB.	The	literature	suggests	that	
in	addition	to	HIV	and	DM,	age,	glycemic	control,	level	of	immunosuppression	and	smear	
status	make	the	TB	chest	radiograph	present	more	atypically.	We	have	shown	that	TBDM	and	
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TBHIV	can	present	atypically	on	chest	radiograph,	however	there	is	still	a	lot	of	typical	
radiographic	presentation	in	these	groups.	Atypical	presentations	may	be	exaggerated	in	
studies	which	erroneously	select	for	one	of	the	potential	confounders	or	effect	modifiers	
mentioned	above.		
	
For	sensitive	screening	and	accurate	diagnosis	clinicians	need	to	understand	the	patterns	of	
atypical	presentation,	and	the	variables	associated	with	it.	Ignorance	of	this	may	lead	to	a	
delayed	or	missed	TB	diagnosis,	worsening	morbidity	and	mortality.	In	circumstances	where	
chest	radiographs	are	being	used	for	screening,	algorithms	may	need	to	be	adjusted	for	
specific	population	groups.		
	
B.5.3	Comparability	to	the	South	African	setting	and	Limitations	
	
While	there	is	a	definite	pattern	of	atypical	chest	radiograph	presentations	for	both	TBDM	
and	TBHIV	patients	the	studies	varied	by	location,	population,	case	definitions	and	
radiograph	reporting	methods.		
	
Our	study	was	conducted	at	a	Primary	Care	clinic	in	Khayelitsha,	a	peri–urban	South	African	
township	with	a	high	TB	and	HIV	burden.	Amongst	TB	patients,	TBDM	co-prevalence	has	
been	reported	to	be	12·6%	(95%	CI	9·7–16·1%),	with	more	than	half	of	the	TBDM	patients	
also	having	HIV	infection	(Oni	et	al,	in	press).	The	literature	varied	substantially	to	our	setting.		
	
All	the	literature	describing	radiographic	manifestations	of	TB	in	HIV-infected	patients	came	
from	high	TB	incidence	regions.	This	is	in	contrast	to	the	TBDM	literature	where	only	5(44,	
49,	52,	61,	64)	out	of	the	24	studies	reviewed	were	conducted	in	regions	with	a	high	TB	
incidence.	The	DM	prevalence	in	TB	in	these	studies	varied	considerably	(ranging	from	2.1%	
(50)	to	34%(55)).	This	may	contribute	to	the	variability	of	the	findings	amongst	the	TBDM	
literature.		
	
The	majority	of	the	studies	reviewed	were	conducted	in	a	hospital	setting.	Participants	in	a	
hospital	setting	may	be	more	morbid	than	those	enrolled	in	a	Primary	Care	setting.	This	may	
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impact	on	chest	radiograph	features,	as	their	disease	may	be	more	advanced	than	what	is	
found	at	the	Primary	Care	level	biasing	the	results.		
	
While	most	of	the	literature	used	reliable	and	valid	methods	to	diagnose	TB	and	HIV,	of	
concern	is	the	variability	in	the	literature	of	DM	definition.	Most	of	the	studies	were	
retrospective	record	reviews.	In	these	studies,	participants	were	classified	as	diabetic	if	
records	described	a	prior	diagnosis	of	diabetes,	use	of	anti-glycemic	medication	and/or	a	
fasting	blood	glucose	or	OGTT	result	compatible	with	diabetes.	Only	2	studies	were	
prospective(52,	61)	and	performed	DM	screening	on	TB	patients.	The	retrospective	nature	of	
the	majority	of	the	studies	could	lead	to	unreliable	estimate	of	DM	prevalence	in	the	cohorts	
examined,	as	DM	may	be	under	diagnosed	in	regions	where	screening	for	DM	in	TB	patients	
is	not	routine.	Misclassification	of	TBDM	patients	could	weaken	the	association	between	
atypical	TB	chest	radiograph	features	and	TBDM.		
	
The	method	and	tools	used	to	report	chest	radiograph	findings	varied	substantially	in	the	
literature.	There	was	no	standardized	or	validated	tool	used	in	the	majority	of	the	studies,	
and	while	experts	were	most	often	asked	to	report	on	the	radiographs,	terminology	and	
features	reported	often	differed.	This	makes	the	comparison	of	some	features	difficult	as	
they	may	on	have	been	under-reported	as	only	a	small	number	of	studies	explored	these	
features.	A	standardized	reporting	method	would	make	the	literature	increasingly	
comparable	and	valid.	In	regions	with	a	low	TB	prevalence	clinicians	may	be	unfamiliar	with	
the	typical	TB	chest	radiograph,	increasing	the	risk	of	misclassification	of	radiographic	
features.		
	
Our	literature	search	was	restricted	to	papers	available	on	the	UCT	libraries	database.	There	
was	a	large	body	of	earlier	research	that	was	not	available	to	review.	These	omitted	papers	
were	mostly	from	the	TBHIV	literature.	However,	there	was	a	strong	consensus	on	the	
features	of	chest	radiography	of	TB	in	HIV	amongst	the	literature	reviewed,	hence	we	do	not	
expect	the	omission	of	the	unavailable	resources	to	bias	our	results.		
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B.6	Conclusion	
	
In	this	review,	we	have	described	the	common	radiographic	findings	of	TB	in	both	patients	
living	with	HIV	or	DM.	We	have	found	that	patients	with	TBHIV	have	more	atypical	chest	
radiographs	and	that	this	may	vary	by	immune	status.	Additionally,	TBDM	patients	have	more	
cavities	and	lower	lobe	infiltrates	than	the	general	TB	population	and	this	presentation	may	
change	according	to	glycemic	control.	Age	and	level	of	immunosupression	may	be	additional	
variables	affecting	chest	radiograph	features	of	TB.		
	
We	have	identified	that	both	DM	and	HIV	modify	the	presentation	of	TB	on	chest	radiograph	
and	that	an	association	with	lower	lobe	lesions	may	be	common	to	both	TBDM	and	HIV-TB	
patients.	Although	there	is	global	recognition	of	the	rising	threat	of	co-morbid	HIV	and	NCDs,	
there	is	a	distinct	lack	of	literature	surrounding	TBDMHIV	patients.	Out	of	63	studies	
reviewed	only	9	alluded	to	TBDMHIV	co-morbidity,	and	amongst	these	none	revealed	a	high	
co-prevalence.	Lack	of	HIV	testing	in	DM	patients	or	DM	screening	in	TB	patients	may	have	
resulted	in	this	finding,	as	well	as	the	low	HIV	prevalence	in	regions	where	the	TBDM	studies	
were	conducted.	With	increasing	co-morbidity	of	HIV	and	NCDs	in	high	HIV	prevalence	
settings	clinicians	need	to	understand	how	these	two	diseases	interact,	especially	with	TB	
and	the	features	thereof.		
	
Our	study	is	a	unique	opportunity	to	examine	the	relationship	between	DM,	HIV	and	TB	in	a	
high	TB,	HIV	and	DM	prevalence	setting.	We	recognize	that	there	is	a	lack	of	literature	
describing	TBDM	and	TBDMHIV	chest	radiography	in	this	setting,	where	the	TB	burden	is	one	
of	the	highest	in	the	world.	Results	from	this	study	will	provide	clinicians	with	essential	
information	to	aid	in	the	diagnosis	of	TB,	which	may	otherwise	be	missed.	This	study	aims	to	
identify	radiographic	manifestations	of	TB	in	persons	with	DM,	and	how	HIV	co-infection	
influences	this	presentation.			
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C.1	Abstract	
	
Background		
The	chest	radiograph	remains	an	important	tool	for	tuberculosis	(TB)	screening	and	
diagnosis.	HIV	and	diabetes	(DM)	are	well-recognized	risk	factors	for	TB,	and	while	many	
studies	have	described	the	independent	effects	of	DM	and	HIV	on	the	chest	radiographic	
presentation	of	TB,	none	have	described	the	effect	of	DM	and	HIV	comorbidity.		
	
Methods		
Posterior-anterior	chest	radiographic	examinations	were	conducted	on	337	pulmonary	TB	
patients	from	primary	care	clinics	in	Khayelitsha,	Cape	Town.	Features	of	chest	radiographs	of	
patients	with	pulmonary	TB	only	(n=84)	were	compared	to	patients	with	comorbid	HIV	
(TBHIV,	n=199),	DM	(TBDM,	n=21),	and	HIV	and	DM	(TBDMHIV,	n=33).		
		
Results		
Compared	to	TB	only,	participants	with	TBDM	had	a	higher	proportion	of	lower	lung	field	
(LLF)	cavitation	(23,8%;	95%	CI:	3,9–43,7%;	p=0,041)	and	were	3,92	times	more	likely	to	have	
LLF	cavitations.	TBDMHIV	had	higher	proportion	of	isolated	LLF	lesions	as	compared	to	TB	
only	participants	(15,2%	vs	3,6%;	p=0,039).	As	CD4	counts	increased,	there	was	an	upward	
trend	towards	an	increase	in	the	proportion	of	cavitations	for	TBDMHIV	participants,	but	this	
was	not	evident	in	TBHIV	participants.				
	
Conclusions	
This	study	reveals	the	atypical	nature	of	chest	radiographs	in	persons	with	TBDM,	TBHIV	and	
TBDMHIV.	The	presence	of	DM	drives	the	LLF	cavitation	in	TB	chest	radiographs.	HIV	and	DM	
comorbidity	alters	this	radiographic	pattern,	although	isolated	LLF	lesions	are	still	more	
prominent	in	TBDMHIV.	These	findings	should	inform	bidirectional	TB	screening	algorithms	in	
patients	with	DM	with	or	without	HIV-infection,	and	highlights	the	important	role	of	
radiographic	examination	in	TB	screening	in	populations	undergoing	epidemiological	
transition.	
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C.2	Background	
	
Although	tuberculosis	(TB)	infection	rates	are	declining	globally,	TB	still	contributes	to	
significant	morbidity	and	mortality	worldwide,	with	10.4	million	individuals	falling	ill	from	TB	
in	2015(1).	While	HIV	is	a	well-recognised	risk	factor	for	the	development	of	TB,	diabetes	
(DM)	has	recently	been	highlighted	as	an	additional	significant	risk	factor(2).	This	is	
increasingly	pertinent	as	the	HIV-infected	population	is	becoming	ever	more	at	risk	of	
developing	non-communicable	diseases	such	as	DM.	This	is	due	to	prolonged	lifespans	
secondary	to		improved	access	to	effective	antiretrovirals	(ARVs),	biomedical	interactions	and	
societal	and	behavioural	changes	(such	as	increasing	urbanisation	and	more	sedentary	
lifestyles)(3,	4).		
	
Early	detection	and	treatment	of	TB	is	essential,	and	is	one	of	the	pillars	of	the	World	Health	
Organisation	(WHO)	End-TB	strategy(5).	Studies	have	shown	that	decreasing	the	delay	
between	presentation,	diagnosis	and	treatment	reduces	TB	transmission	and	improves	
patient	outcomes(6,	7).	New	diagnostic	technologies,	such	as	GeneXpert,	may	decrease	the	
delay	to	treatment	through	rapid	diagnosis(8),	however	chest	radiography	still	has	a	role	in	
TB	diagnosis.	The	WHO	recently	released	recommendations	on	the	use	of	chest	radiography	
in	TB	diagnosis	and	screening(9).	Where	the	chest	radiograph	was	previously	placed	at	the	
end	of	diagnostic	algorithms,	its	importance	higher	up	in	the	algorithm	is	now	recognised,	
especially	when	bacteriological	confirmation	of	disease	is	not	available(10).	Clinicians	need	to	
be	adept	at	reading	and	interpreting	pulmonary	TB	(PTB)	chest	radiographs	so	as	not	to	delay	
diagnosis	and	treatment.	Undiagnosed	TB	may	result	in	increased	morbidity	and	mortality,	
especially	in	HIV-infected	patients(11).	The	rapid	epidemiological	transition	occurring	in	many	
countries	with	a	high	TB	burden	is	accompanied	by	a	change	in	patterns	of	TB	co-morbidity	
with	an	increasing	prevalence	of	TB/DM/HIV	comorbidity.	This	changing	patterns	of	disease,	
impact	on	the	clinical	presentation	of	PTB	including	the	chest	radiograph	presentation.		
	
The	chest	radiographic	presentation	of	PTB	in	the	HIV-infected	population	has	been	well	
described	with	most	patients	presenting	with	features	of	primary	infection,	such	as	hilar	
adenopathy,	pleural	effusions,	lobar	consolidation	and	miliary	disease	on	chest	
radiograph(12),	with	increasingly	atypical	features	as	CD4	counts	decline(13,	14).	Similar	
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studies	have	been	conducted	in	patients	with	DM	and	TB	(TBDM)(15,	16).	However,	the	
majority	of	these	studies	have	been	conducted	in	areas	of	low	TB	incidence	with	only	one	
early,	small	study	being	from	South	Africa(17).	TBDM	patients	have	been	reported	to	present	
with	more	lower	lung	field	opacifications	and	increased	cavitation(15,	16,	18).	It	has	been	
suggested	that	the	abnormalities	found	in	both	HIV-infected	patients	with	TB	(TBHIV)	and	
TBDM	patients	are	due	to	immune	dysregulation	and	suppression	of	cell	mediated	
immunity(19).	The	combined	effect	of	DM	and	HIV	comorbidity	on	the	chest	radiographic	
features	of	PTB	has	not	yet	been	described,	as	the	TBDM	literature	have	either	excluded	HIV-
infected	participants	or	have	been	retrospective	in	nature,	with	no	active	screening	for	HIV.		
	
The	primary	objective	of	this	study	is	to	describe	the	atypical	chest	radiographic	features	of	
PTB	in	patients	with	comorbid	DM	in	a	population	with	a	high	TB,	DM	and	HIV	burden.	The	
secondary	objectives	are	to	investigate	the	effect	of	concurrent	HIV	infection	on	these	
characteristics	and	how	disease	severity	(HIV	or	DM)	effects	this	presentation.		
	
C.3	Methods	
	
C.3.1	Study	setting	and	recruitment	
As	part	of	a	larger	study	investigating	the	association	between	DM	and	TB,	participants	with	
TB	were	recruited	between	June	2013	and	October	2015.	Participants	were	recruited	from	
two	arms	of	the	parent	study:	the	first	arm	being	a	cross-sectional	study	screening	TB	
patients	for	DM	(Arm	A),	the	second	arm,	a	cross-sectional	study	screening	DM	patients	for	
TB	(Arm	B).	All	participants	were	recruited	from	Khayelitsha,	a	predominantly	Black-African,	
peri-urban	township	in	Cape	Town,	South	Africa,	with	a	population	of	approximately	390,000	
people(20).	In	Khayelitsha	the	TB	case	notification	rate	is	>1600/100	000(21)	with	an	
antenatal	HIV	prevalence	of	37,1%(22),	and	the	DM	prevalence	is	approximately	13%(23).		
Participants	who	were	recruited	from	arm	A	were	recruited	from	Ubuntu	clinic,	a	primary	
care	TB	and	ARV	clinic,	whereas	the	arm	B	participants	were	recruited	from	the	DM	clinic	at	
Site	B	primary	health	care	facility.	Both	clinics	are	situated	on	the	same	property	and	service	
the	same	population.		
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To	investigate	the	chest	radiographic	features	of	PTB	in	DM	patients,	we	included	all	
participants	from	both	arms	of	the	parent	study	who	had	a	proven	diagnosis	of	TB	(as	per	
national	guidelines)	and	a	chest	radiograph	taken	at	recruitment.	Breakdown	of	the	
recruitment	process	is	shown	in	Figure	1.			
	
Figure	C-1:	Participant	recruitment	diagram	
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Total	number	in	study	N=337	across	4	TB	categories:	
	
TB	only	–	84		 	 		TB	and	HIV	–	199	 	 		TB	and	DM		–	21	 	 		TB,	HIV	and	DM		-	33	
	
Number	of	DM	patients	
screened	for	TB:	461	
	
Number	diagnosed	with	
TB:	13	
	
TB	and	DM	-	8	
TB,	DM	and	HIV	–	5	
	
Number	of	TB	patients	
screened	for	DM:	414	
	
Number	included	in	study:	
324	
	
90	excluded	due	to	lack	of	
chest	radiograph	
TB	and	DM:	
16	
TB,	DM	and	
HIV:	25	
	
TB	only:		
84	
	
TB	and	HIV:	
199	
	
	 46	
C.3.2	Data	Collection		
	
Clinical	characteristics:	
Participants	in	arm	A	were	screened	for	DM	using	a	fasting	blood	glucose	(FBG)	test,	two	
hour	oral	glucose	tolerance	test	(2hBG)	and	glycosylated	haemoglobin	(HbA1c)	test.	
Participants	were	considered	diabetic	if	they	had	a	prior	diagnosis	of	DM,	were	on	oral	anti-
glycaemic	agents	or	insulin,	or	met	the	biochemical	criteria	of	DM	by	any	of	the	three	tests	
above,	as	per	the	American	Diabetes	Association	guidelines	(FBG	>7.0mmol/l,	2hBG	
>=11.1mmol/l	or	an	HbA1c	>6.5%)(24).	Participants	from	arm	B	were	recruited	from	a	DM	
clinic	and	all	had	a	prior	diagnosis	of	DM.	All	participants	underwent	spontaneous,	or	if	
required,	induced	sputum.	Sputum	samples	underwent	GeneXpert	processing	and	drug	
resistance	testing,	and	were	sent	for	smear	microscopy	if	the	GeneXpert	result	was	positive	
or	if	participants	were	HIV-infected.	Participants	were	classified	as	having	TB	if	they	were	
found	to	be	smear	microscopy	positive	for	acid-fast	bacilli;	have	isolation	or	identification	of	
Mycobacterium	tuberculosis	by	culture	or	Genexpert	or	have	TB	compatible	clinical	signs	and	
symptoms	(including	typical	chest	radiograph)	and	resolution	of	symptoms	after	TB	
treatment.	All	participants	in	both	arms	were	offered	HIV	testing	and	counselling.	A	
standardized	STEPs	chronic	disease	risk	factor	tool(25)	was	completed	by	a	clinical	research	
worker	for	all	participants.		
	
Chest	radiography:	
Posterior-anterior	chest	radiographic	examinations	were	conducted	by	an	experienced	
radiographer	on	all	participants.	All	radiographs	were	read	by	two	clinicians,	a	radiologist	and	
an	infectious	disease	research	medical	officer.	Both	readers	were	blinded	to	the	DM	and	HIV	
status	of	the	participant.	If	there	was	discordance	between	the	two	reports,	a	third	reader	
was	used	and	consensus	was	reached.	A	standardized	chest	radiographic	reading	and	
reporting	system	(CRRS)	tool	was	used	to	report	on	all	chest	radiographs(26).	The	CRRS	has	
been	previously	validated	for	epidemiological	research(26)	and	was	chosen	to	decrease	inter-
reader	variability.	It	consists	of	a	tick	sheet	to	capture	the	absence	or	presence	and	lobar	
location	of	opacifications,	cavitations,	miliary	disease,	pleural	effusions	and	
lymphadenopathy.	
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C.3.3	Statistical	Analysis	
Participant	characteristics	were	described	using	descriptive	statistics.	The	clinical	and	
radiographic	characteristics	of	participants	in	the	four	TB	categories	were	compared	using	
Pearson’s	chi-squared	test	and	Fischer’s	exact	test,	as	well	as	Wilcoxon	rank-sum	test	for	
continuous	data.	The	most	common	atypical	radiographic	features	were	identified	for	each	
TB	category.		Variation	in	chest	radiographic	features	by	CD4	cell	count	and	glycaemic	control	
were	also	described.	Participants	with	HIV	were	categorised	into	CD4	cell	counts	of	above	
and	below	500cells/mm3	based	on	national	ARV	initiation	criteria	at	the	time	of	the	study(27)	
and	an	HbA1c	of	10%	or	more	was	considered	severe	hyperglycaemia.	Multivariate	logistic	
regression	was	used	to	determine	the	association	between	the	identified	common	atypical	
TB	chest	radiographic	features	(lower	lung	field	opacification	and	consolation	and	isolated	
lower	lung	field	lesions)	and	DM	status,	and	to	examine	the	potential	effect	modification	of	
HIV	infection	on	this	association	through	the	addition	of	an	interaction	term.	Smoking	status	
and	previous	history	of	TB	were	found	to	have	significant	associations	with	the	atypical	
presentations	and	were	added	to	the	final	models.	Odds	ratios	and	95%	confidence	intervals	
were	calculated.	Significance	testing	was	performed	using	two	sided	P-values	of	<0.05.	The	
presence	of	upper	lobe	cavitation	is	traditionally	the	most	pathognomonic	feature	of	PTB.	In	
our	literature	review	we	found	that	lower	lung	field	cavitation	was	the	most	common	atypical	
finding	in	TBDM.	As	the	prevalence	of	lower	lung	field	cavitation	varied	between	50%	–	86%	
for	TBDM	patients	and	20%	-	46%	for	patients	with	TB	only,	a	sample	of	37	TBDM	and	37	TB	
only	participants	was	needed	to	detect	a	difference	in	lower	lobe	cavitation	at	a	power	of	
80%	and	alpha	at	0,05(15,	18).	All	statistical	analysis	was	conducted	on	Stata	13.1	(StataCorp,	
College	Station,	TX,	USA).	
	
C.4	Ethics	
All	participants	underwent	informed	consent	in	their	first	language	and	the	study	was	
approved	by	the	University	of	Cape	Town	Human	Research	Ethics	Committee	(HREC	
373/2016).	
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C.5	Results	
A	total	of	337	participants	with	TB	were	included	in	the	study.	Participants	were	stratified	by	
TB	category:	participants	with	only	TB	(24,9%),	participants	with	TB	and	HIV	(TBHIV:	59,1%),	
participants	with	TB	and	DM	(TBDM:	6,2%)	and	participants	with	TB,	DM	and	HIV	(TBDMHIV:	
9,8%).		
	
C.5.1	Participant	characteristics	
	
Diabetes:	There	were	54	patients	with	DM	in	the	study.	The	proportion	of	DM	patients	did	
not	differ	between	males	and	females,	with	58,7%	being	female	(p=0,153).	DM	participants	
were	overall	older	than	non-DM	(median	age:	45,4	IQR:	37,0–57,2	vs	35,6	IQR:	29,6–42,1	
years;	p	<0,001),	with	the	TBDM	category	having	the	oldest	participants	amongst	the	TB	
categories	(Table	C-1).	DM	diagnosis	was	largely	driven	by	HbA1c	(table	XX).	The	median	
HbA1c	for	all	participants	with	DM	was	7,4%	(IQR:	6,6	–	10,9%),	with	52,4%	of	the	TBDM	and	
28,6%	of	the	TBDMHIV	participants	having	had	an	HbA1c	of	10%	or	greater.	
	
HIV:	The	overall	HIV	prevalence	in	this	sample	was	68,8%	(n	=	232;	95%	CI:	63,9	–	73,8%).	A	
recent	CD4	cell	count	was	recorded	for	209	of	these	participants.	The	overall	median	CD4	cell	
count	was	low	(203	cells/mm3;	range	2-1172	cells/mm3).	No	significant	differences	in	CD4	cell	
count	were	found	by	gender,	age	or	DM	status.	As	shown	in	Table	C-1,	median	CD4	cell	
counts	did	not	differ	between	TBHIV	and	TBDMHIV	categories	(p=0,263).		
	
Given	the	potential	impact	of	smoking	and	a	previous	TB	history	on	chest	radiograph	
presentation,	these	variables	were	further	explored	below:			
 
Smoking:	Less	than	a	quarter	of	the	overall	sample	were	smokers	(Table	C-1).	TBDMHIV	
participants	had	a	significantly	lower	proportion	of	smokers	(6,1%	95%	CI:	2,5	–	14,7%)	as	
compared	to	any	other	TB	category	(Table	C-1).	Overall	and	across	all	four	TB	categories,	
males	were	more	likely	to	smoke	than	females	[35,2%	(95%	CI:	28,5	–	41,9%)	vs	4,2%	(95%	
CI:	0,87	–	7,5%),	p<0,001].	Median	ages	for	smokers	and	non-smokers	were	similar	for	all	TB	
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categories,	apart	from	the	TB	only	category	where	non-smokers	were	significantly	younger	
than	smokers	(median	age:	28,7	vs	42,0	years;	p=0,045).	
 
Previous	TB:	The	majority	of	participants	were	previously	TB	naïve	(70%;	95%	CI	64,7	–	
74,9%),	with	no	differences	in	this	proportion	in	HIV-infected	and	uninfected	participants	
(31,9%	vs	23,8%;	p=	0,131),	or	participants	with	or	without	DM	(22,2%	vs	30,7%;	p=0,208).	
Participants	in	the	TBHIV	category	had	a	higher	reported	prevalence	of	previous	TB	
compared	to	TB	only	or	TBDMHIV	participants	(Table	C-1:	p=	0,027	and	p=0,026	
respectively).	Participants	with	previous	TB	were	slightly	older	than	TB	naïve	participants	
(median	age:	37,9	IQR:	32,4–46,4	vs	35,7	IQR:	28,4–43,1	years,	p=0,011).	
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Table	C-1:	Participant	characteristics	by	TB	category	
	 OVERALL	
(n=337)	
	 TB		
(n=84)	
TBHIV	
(n=199)	 P-value*	
TBDM		
(n=21)	 P-value*	
TBDMHIV		
(n=	33)	 P-value*	
Sex		
Female	(%)	
Male				(%)	
	
145	
(43,0)	
192	
(57.0)	
	 	
18	(21,4)	
66	(78,6)	
	
99	(49,8)	
100	
(50,3)	
	
0,000	
	
10	(47,6)	
11	(52,4)	
	
0,015	
	
18	(54,6)	
15	(45,4)	
	
0,000	
Age	(median	
years)	
(IQR)	
36,6		
(30,0-
43,9)	
	 31,0		
(25,3	-	
42,5)	
36,5		
(31,5	-	
41,6)	
0,002	 54,8		
(45,3	-	
60,5)	
0,000	 40,8		
(32,8	-	
51,4)	
0,005	
Age	category	
(%)	
	 	 	 	 0,000	 	 0,000	 	 0,000	
<25	years	
	 23	(6,8)	
	 13	(15,5)	 5	(2,5)	 	 1	(4,8)		 	 4	(12,1)		 	
25	–	35	years	 109	
(32,3)	
	 35	(41,7)	 68	(34,2)	 	 1	(4,8)		 	 5	(15,2)		 	
35	–	45	years	 121	
(35,9)	
	 19	(22,6)	 88	(44,2)	 	 3	(14,3)	 	 11	(33,3)	 	
>45	years	 84	(24,9)	 	 17	(20,2)	 38	(19,1)	 	 16	(76,2)	 	 13	(39,4	 	
HbA1c	-	
median	
(IQR)	
(n	=	372)a	
5,8%		
(5,5	-	
6,1)	
	 5,7%		
(5,5	–	
6,0)	
	
5,7%			
(5,4	-		
5,7)		
(n	=	195)		
0,772	 10%		
(6,75	-	
12,2)		
(n	=	20)	
0,000	
6,9%		
(6,5	-		9,5)	
	
0,000	
CD4	cell	count		
–	median	
(cells/mm3)	
(n	=	209)a	
203		
(85	-332)	
	
	 NA	 203,5		
(85	-337)	
(n=182)	
-	 NA	 -	 202		
(74-309)	
(n=27)	
	
CD4	<500	
cells/mm3	(%)	
(n	=209)a	
194	
(92,8)	
	
	 NA	 169	
(92,9)	
(n=182)	
-	 NA	 -	 25	(92,6)	
(n=27)	
	
Smoker	(%)	
(n	=	330)a	
73	(22)		
	
	 22	(26,5)	
(n=83)	
45	(23,2)	
(n=194)	
0,556	 4	(20)	
(n=20)	
0,548	 2	(6,1)	
(n=33)	
0,014	
Previous	TB	
history	(%)	
99	(29,4)	
	
	 18	(21,4)	 69	(35,2)	 0,027	 7	(33,3)	 0,252	 5	(15,2)	 0,442	
DM	diagnosis	
Known	DM	
New	DM	
diagnosis	
	
	
28	(8,3)	
26	(7,7)	
	 NA	 NA	 	 	
	
15	(71,4)	
6			(28,6)	
	 	
	
13	(39,4)	
20	(60,6)	
	
Microbiological
ly	confirmed	TB	
261	
(77,4)	
	 66		
(78,6)	
146	
(73,4)	
0,356	 18		
(85,7)	
0,347	 27		
(81,8)	
0,483	
	
IQR:	inter-quartile	range;	HbA1c:	Glycosylated	haemoglobin	
*as	compared	to	TB	only	participants	
awhere	participant	data	are	missing,	the	denominator	is	provided	in	parenthesis		
	
	
	
	
	
	
	
	
	 51	
Table	C-2:	Diabetes	diagnosis	by	diagnostic	test	
	 OVERALL	(N=54)	 NEW	DM	(N=26)	 OLD	DM	(N=28)	
Diagnostic	
test	(%)	
FBG	 42,6	(29,2	–	56,8)	 30,8	(14,2	–	51,8)	 53,6	(33,9	–	72,5)	
2hBG	 18,5	(9,3	–	31,4)	 34,6	(17,2	–	55,7)		 3,6	(0,09	–	18,3)	
Hba1c	 87,0	(75,1	-		94,6)	 76,9	(56,3	–	91,0)		 96,4	(81,7	–	99,9)	
	
C.5.2	Radiographic	findings	
	
Overall,	the	most	common	radiographic	finding	was	opacification	(81%;	95%	CI:	76,8	–	
85,2%),	with	the	distribution	of	opacification	being	predominantly	upper	lobe	(UL)	(71,2%;	
95%	CI:	66,4	–	76,1%).	Almost	half	of	the	sample	had	cavitation	(47,8%;	95%	CI:	42,4	–	
53,1%),	the	majority	of	which	were	UL.	However	10,4%	(n=35;	95%	CI:	7,1	–	13,7%)	of	the	
sample	had	lower	lung	field	(LLF)	cavitation.	Although	pleural	effusions	(24%;	95%	CI:	19,5	–	
28,6%)	and	lymphadenopathy	(37,9%;	95%	CI:	32,7	–	43,1%)	were	found	fairly	frequently	in	
the	overall	sample,	the	proportion	of	these	findings	did	not	vary	significantly	across	the	TB	
categories	(Table	C-3).	The	most	infrequent	radiographic	finding	was	a	miliary	pattern	(2,7%;	
95%	CI:	0,9	–	4,4%)	and	this	did	not	vary	by	TB	category	(Table	C-3).		
	
C.5.2.1	Atypical	radiographic	presentations	
	
TBDM:	All	of	the	TBDM	participants	had	some	parenchymal	abnormality,	with	76,2%	(95%	CI:	
56,3	–	96,1%)	and	23,8%	(95%	CI:	3,9	–	43,7%)	having	LLF	opacification	and	cavitation	
respectively.	TBDM	participants	were	found	to	have	more	frequent	LLF	cavities	(Table	C-3;	
p=0,041)	than	TB	only	participants.	Isolated	LLF	opacification	was	present	in	14,3%	(n=3;	95%	
CI:	2,0–30,6%)	of	TBDM	participants,	compared	to	3,6%	of	TB	only	patients	(p=0,093).	If	LLF	
opacification	and	cavitation	were	pooled,	TBDM	participants	had	a	higher	proportion	of	
pooled	LLF	involvement	compared	to	participants	with	TB	only	(76,2%	vs	61,9%;	p	=	0,220)	
but	this	difference	was	not	significant.	However,	TBDM	participants	with	an	HbA1c	of	more	
than	10%	(n=11)	had	higher	proportion	of pooled	LLF	involvement	(90,9%	vs	61,9%	p=0,052)	
and	isolated	LLF	involvement	(27,3%	vs	3,6%;	p=	0,019)	compared	to	TB	only	participants.		
	
TBHIV:	TBHIV	participants	had	a	high	proportion	of	normal	chest	radiographs	(15,1%;	95%	CI	
10,1	–	20,1%)	and	hence,	fewer	parenchymal	abnormalities	when	compared	to	participants	
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with	TB	only	(84,9%	vs	96,4%;	p=0,006).	Strikingly,	the	proportion	of	UL	cavitation	amongst	
TBHIV	participants	was	almost	50%	lower	than	TB	only	participants	(35,2	vs	64,3;	p	<	0,001).	
No	significant	difference	was	found	between	TBHIV	and	TB	only	participants	with	regard	to	
LLF	opacification	or	cavitation	(Table	C-3).	The	degree	of	immunosuppression	affected	
radiographic	presentation.		As	the	CD4	cell	count	increased,	chest	radiographs	became	less	
atypical,	with	more	frequent	UL	opacification	(73,3%;	95%	CI:	56,0	–	90,1%).	However,	
cavitation	did	not	follow	this	trend	with	proportion	of	UL	and	LLF	cavitation	remaining	similar	
for	TBHIV	participants	with	CD4	cell	counts	above	and	below	500	cells/mm3	(Figure	3),	with	
UL	cavitation	remaining	significantly	lower	than	TB	only	participants	(Tables	3	and	4).				
	
TBDMHIV:	TBDMHIV	participants	presented	similarly	to	the	TBHIV	category,	namely,	a	high	
proportion	of	normal	chest	radiographs	(15,2%;	95%	CI	5,1-31,9%);	fewer	parenchymal	
abnormalities	(84,9%	vs	96,4%,	p=0,006)	and	less	frequent	UL	involvement	(opacifications	or	
cavitations,	Table	C-3)	than	TB	only	participants.	The	TBDMHIV	category	had	the	lowest	
proportion	of	radiographs	with	LLF	opacification	(33,3%;	95%	CI:	16,4	-	50,3%)	and	cavitation	
(6,1%;	95%	CI:	2,5	–	14,7%)	of	all	the	TB	categories	(Table	C-3).	Additionally,	the	TBDMHIV	
category	had	a	higher	proportion	of	participants	with	isolated	LLF	lesions	(n=5)	as	compared	
to	the	TB	only	(n=3)	category	(15,2%	vs	3,6%;	p=0,039),	and	this	proportion	was	similar	to	
that	of	the	TBDM	category	(n=3,	14,3%;	p	=	0,626).	Only	8	TBDMHIV	participants	had	a	CD4	
cell	count	greater	than	500cells/mm3.	When	stratified	by	CD4	count	a	similar	pattern	to	
TBHIV	is	observed,	specifically,	increasing	UL	opacification	as	CD4	count	increased	(Figure	4).	
There	was	a	decline	in	frequency	of	LLF	opacifications	for	TBDMHIV	participants	with	a	CD4	
cell	count	of	>500cells/mm3	(n=1)	(Table	C-5).	In	contrast	to	TBHIV	participants,	the	
proportion	of	UL	and	LLF	cavitation	increased	for	TBDMHIV	participants	as	CD4	cell	count	
increased	(Figure	5)	with	no	significant	difference	in	frequency	of	UL	and	LLF	cavitation	
between	TBDM	and	TBDMHIV	participants	with	a	CD4	cell	count	>500mm3	(Table	C-5).	
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Table	C-3:	Radiographic	features	of	Pulmonary	TB	across	TB	categories	
FEATURE	(%)	 OVERALL		
(N=337)	
	 TB		
(N=84)	
TBDM		
(N=21)	
P-valuea	
TBHIV		
(N=199)	
P-valuea	
TBDMHIV		
(N=	33)	
P-valuea	
Normal	radiograph	 38	(11,3)	 		 3	(3,6)	 1	(4,8)	 0,508	 30	(15,1)	 0,006	 5	(15,2)	 0,039	
Any		
opacification	
273	(81,0)	 	 76	(90,5)	 21	(100)	 0,156	 150	(75,4)	 0,004	 26	(78,8)	 0,123	
Upper	lobe	opacification	 240	(71,2)	 		 73	(86,9)	 17	(81,0)	 0,348	 129	(64,8)	 0,000	 21	(63,6)	 0,004	
Lower	lung	field	opacification	 181	(53,7)	 	 51	(60,7)	 16	(76,2)	 0,187	 103	(51,8)	 0,167	 11	(33,3)	 0,008	
Any	cavitation	 161	(47,8)	 		 57	(67,9)	 11	(52,4)	 0,184	 83	(41,7)	 0,000	 10	(30,3)	 0,000	
Upper	lobe	cavitation	 143	(42,4)	 	 54	(64,3)	 11	(52,4)	 0,315	 70	(35,2)	 0,000	 8	(24,2)	 0,000	
Lower	lung	field	cavitation	 35	(10,4)	 		 6	(7,1)	 5			(23,8)	 0,041	 22	(11,1)	 0,314	 2	(6,1)	 0.598	
Miliary	pattern	 9	(2,7)	 	 3	(3,6)	 0	 0,505	 5	(2,5)	 0,439	 1	(3,0)	 0,680	
Pleural	effusion	 81	(24)	 		 16	(19,1)	 6	(28,6)	 0,249	 53	(26,6)	 0,175	 6	(18,2)	 0,914	
Lymphadenopathy	 127	(37,9)	 	 31	(36,9)	 7	(33,3)	 0,761	 75	(38,1)	 0,853	 14	(42,4)	 0,581	
acompared	to	TB	category	
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Figure	 C-2:	 Proportion	 of	 opacification	 for	 TBHIV	 participants	 by	
increasing	CD4	cell	count	compared	to	TB	participants	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 C-3:	 Proportion	 of	 cavitations	 for	 TBHIV	 participants	 by	
increasing	CD4	cell	count	compared	to	TB	participants	
	
	
	
	
	
	
	
	
	
	
	
	
*p	<0.05	
	
*p	<0.05	
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Figure	C-4:	Proportion	of	opacification	for	TBDMHIV	participants	by	
increasing	CD4	cell	count	compared	to	TBDM	participants	
	
	
	
	
	
	
Figure	 C-5:	 Proportion	 of	 cavitations	 for	 TBDMHIV	 participants	 by	
increasing	CD4	cell	count	as	compared	to	TBDM	participants	
	
	
	
*p	<0.05	
	
*p	<0.05	
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Table	C-4:	Radiographic	 features	 across	 TB,	 TBHIV	and	TBDMHIV	 categories	when	CD4	 cell	
count	<500	cells/mm3	
	
FEATURE	(%)	 TB		
(N=84)	
TBHIV	
(N=169)	
P-value	 TBDM	
(N=21)	
TBDMHIV	
(N=25)	
P-value	
Parenchymal	
abnormality	
81	(96,4)		 142	(84)	 0,004	 21	(100)	 21	(84)	 0,078	
Any	opacification	 76	(90,5)	 126	(74,5)	 0,003	 21	(100)	 19	(76)	 0,019	
Upper	lobe	
opacification	
73	(86,9)	 107	(63,3)	 <0,001	 17	(81,0)	 14	(56)	 0,072	
Lower	lung	field	
opacification	
51	(60,7)	 89	(52,7)	 0,225	 16	(76,2)	 10	(40)	 0,014	
Any	cavitation	 57	(67,9)	 71	(42)	 <0,001	 11	(52,4)	 6	(24)	 0,047	
Upper	lobe	cavitation	 54	(64,3)	 59	(34,9)	 <0,001	 11	(52,4)	 5	(20)	 0,022	
Lower	lung	field	
cavitation	
6	(7,1)	 20	(11,8)	 0,247	 5	(23,8)	 1	(4)	 0,060	
	
	
	
Table	C-5:	Radiographic	 features	 across	 TB,	 TBHIV	and	TBDMHIV	 categories	when	CD4	 cell	
count	>500	cells/mm3	
	
FEATURE	(%)	 TB		
(N=84)	
TBHIV		
(N=30)	
P-
value	
TBDM		
(N=21)	
TBDMHIV	
(N=8)	
P-value	
Parenchymal	
abnormality	
81	(96,4)		 27	(90)	 0,176	 21	(100)	 7	(87,5)	 0,309	
Any	opacification	 76	(90,5)	 24	(80)	 0,133	 21	(100)	 7	(87,5)	 0,576	
Upper	lobe	
opacification	
73	(86,9)	 22	(73,3)	 0,087	 17	(81,0)	 7	(87,5)	 0,721	
Lower	lung	field	
opacification	
51	(60,7)	 14	(46,7)	 0,182	 16	(76,2)	 1	(12,5)	 0,011	
Any	cavitation	 57	(67,9)	 12	(40)	 0,007	 11	(52,4)	 4	(50)	 0,258	
Upper	lobe	
cavitation	
54	(64,3)	 11	(36,7)	 0,009	 11	(52,4)	 3	(37,5)	 0,134	
Lower	lung	field	
cavitation	
6	(7,1)	 2	(6,7)	 0,647	 5	(23,8)	 1	(12,5)	 0,483	
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C.5.3	Effect	of	HIV	on	TBDM	presentation	
	
The	results	from	Table	C-6	highlight	LLF	involvement	as	a	characteristic	feature	of	the	TBDM	
chest	radiograph.	Multivariate	logistic	regression	was	used	to	explore	the	associations	
between	LLF	involvement	(opacifications,	cavitations	and	isolated	lesions)	and	TB	category,	
as	compared	to	TB	only.	After	adjustment	for	HIV	status,	TBDM	had	a	3,92	fold	increased	
odds	of	LLF	cavitation	as	compared	to	TB	only	participants	(95%	CI	1,04–14,73;	p=0,043).	
While	not	significant	there	appears	to	be	an	increasing	trend	of	isolated	LLF	lesion	in	TBDM	
participants	(aOR	4,90;	95%	CI	0,90-26,5;	p=0,065).	A	previous	history	of	TB	was	the	only	
other	variable	with	a	significant	positive	association	with	LLF	lesions	(both	opacification	and	
cavitation,	aOR	2,18,	95%	CI	1,30-3,64;	p=0,003	and	aOR	2,14	95%	CI	1,02-4,46;	p=0,043	
respectively).	There	was	no	significant	association	between	TBHIV	or	TBDMHIV	and	LLF	
involvement.		
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Table	C-6:	Multivariate	Logistic	Regression	
	
	 LOWER	LUNG	FIELD	OPACIFICATION	 LOWER	LUNG	FIELD	CAVITATION	 ISOLATED	LOWER	LUNG	FIELD	LESIONS	
	 OR	(95%	CI)	 P-
value	
aOR		 P-
value	
OR	(95%	CI)	 P-
value	
aOR		 P-
value	
OR	(95%	CI)	 P-
value	
aOR		 P-value	
TBDM	 	0,79				(0,44	-	1,43)	 0,437	 	1,71				(0,56	-	5,21)	 0,346	 	1,41				(0,58	-	3,43)	 0,450	 3,92				(1,04	-	14,73)	 0,043	 2,28				(0,95	-	5,50)	 0,065	 4,90				(0,90	-	26,5)	 0,065	
TBHIV	 	0,58				(0,34	-	0,93)	 0,025	 	0,63				(0,37	-	1,09)	 0,099	 	0,94				(0,44	-	2,02)	 0,880	 1,39					(0,53	-		3,63)	 0,499	 	1,73			(0,68	-	4,42)	 0,248	 2,67				(0,76	–	9,42)	 0,127	
TBDMHIV	 -	 	 	0,46				(0,20	–	1,03)	 0,061	 -	 	 0,63					(0,13	-	2,80)	 0,076	 -	 	 1,75				(0,59	-	5,21)	 0,319	
Previous	
TB	history	
	2,00				(1,22	-	3,25)	 0,006	 	2,18				(1,30	-	3,64)	 0,003	 	2,28					(1,11	-	4,68)	 0,025	 2,14					(1,02	-	4,46)	 0,043	 0,76					(0,31	-	1,85)	 0,547	 0,74				(0,30		-	1.83)	 0,509	
Smoker	 	0,64				(0,38	-	1,07)	 0,091	 	0,51				(0,29	-	0,88)	 0,016	 	0,90					(0,38	-	2,17)	 0,820	 -	 	 0,56					(0,19	-	1,68)	 0,302	 -	 	
Age	 	1,00				(0,98	-	1,02)	 0,747	 -	 	 	1,01					(0,99	-	1,04)	 0,512	 -	 	 1,02					(0,98	-	1,05)	 0,304	 -	 	
Sex	 	1,10				(0,72	-	1,72)	 0,646	 -	 	 	1,07					(0,52	-	2,21)	 0,847	 -	 	 0,62					(0,29	-	1,35)	 0,229	 -	 	
OR	=	Odds	Ratio;	aOR	=	adjusted	Odds	Ratio;	CI	=	Confidence	Interval	
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C.6	Discussion	
	
C.6.1	Lower	lung	field	involvement	in	TBDM	and	TBDMHIV	
	
Lower	lung	field	involvement	is	considered	an	atypical	presentation	of	pulmonary	TB.	We	
found	that	a	high	proportion	(76,2%)	of	TBDM	participants	in	our	study	had	LLF	opacification,	
with	23,8%	having	LLF	cavitation.	LLF	cavitation	was	almost	four	times	more	likely	in	TBDM	
participants	as	compared	to	TB	only.	In	TBDMHIV	participants,	diabetes,	as	compared	to	HIV-
related	immunosuppression,	appears	to	be	the	driver	of	LLF	cavitation,	as	on	adjustment	for	
the	degree	of	the	immunosuppression,	TBDMHIV	participants	had	an	increased	frequency	of	
LLF	cavitation,	similar	to	TBDM.	This	finding	is	supported	by	Perez(15)	and	Chiang(28),	who	
both	conducted	studies	in	high	TB	incidence	settings.	DM	is	now	a	well-recognized	risk	factor	
for	TB	and	a	recently	completed	study	from	Khayelitsha	revealed	that	61,5%	of	DM	found	
amongst	TB	participants	was	undiagnosed	(Oni	et	al,	in	press),	emphasizing	the	need	to	
screen	TB	patients	for	DM.	This	finding	of	increased	LLF	cavitation	on	the	TB	chest	radiograph	
in	TBDM	patients	may	be	utilized	in	targeted	DM	in	TB	screening	algorithms	by	suggesting	
potential	DM	comorbidity.	Furthermore,	this	has	the	potential	to	improve	DM	outcomes	by	
earlier	case	detection	and	treatment.	
	
 As	reported	in	previous	studies	(18,	28),	this	study	found	a	high	proportion	of	isolated	LLF	
opacification	in	TBDM	and	TBDMHIV	patients	(14,3%	and	15,2%	respectively).		A	recent	study	
that	screened	DM	patients	for	TB	in	South	Africa	found	a	significant	prevalence	of	both	
asymptomatic	and	smear	microscopy	negative	TB	in	TBDM	patients	(Berkowitz	et	al,	under	
review).	Given	the	risk	that	atypical	TB	presentations	may	lead	to	a	delayed	diagnosis	of	PTB,	
contributing	to	continued	transmission	and	increased	mortality	(6,	7),	these	findings highlight	
the	need	for	clinicians	to	be	aware	of,	and	investigate,	atypical	presentations	of	TB	in	DM	co-
morbid	patients	in	order	to	avoid	delays	in	TB	diagnosis. 
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C.6.2	The	presence	of	HIV-infection	modifies	the	atypical	TBDM	chest	radiographic	features	
	
TBHIV	participants	in	this	study	presented	similarly	to	what	has	been	described	in	previous	
literature,	specifically,	they	had	more	normal	chest	radiographs(29),	fewer	upper	lobe	
infiltrates(30-32)	and	fewer	cavities(29,	30,	33,	34)	compared	to	HIV-uninfected	TB	patients.	
To	our	knowledge,	our	study	is	the	first	which	describes	the	interaction	between	DM	and	HIV	
with	regards	to	the	TB	chest	radiograph	presentation.	We	found	that	TBDM	was	significantly	
associated	with	LLF	cavitations,	however	no	statistically	significant	associations	were	found	
between	TBDMHIV	and	LLF	involvement.	This	suggests	that	the	presence	of	HIV	infection	
suppresses	the	typical	TBDM	chest	radiograph	appearance.		While	the	body	of	evidence	
supporting	LLF	involvement	in	TBDM	participants	is	strong,	there	are	a	number	of	studies	
that	disagree	with	this	finding(35-38).	Of	these,	the	only	study	which	actively	screened	for	
HIV	was	by	Gil-Santana	et	al(36)	and	found	that	none	of	the	sample	were	infected.	Of	the	
remaining	studies	one	did	not	mention	HIV	testing(37)	and	the	others	were	retrospective	
record	reviews(35,	38).	This	could	have	resulted	in	misclassification	of	HIV	status	if	results	
were	not	recorded	or	patients	not	tested.	Lack	of	ascertainment	of	HIV	status	amongst	TBDM	
participants	may	have	led	to	these	studies	not	finding	the	typical	LLF	lesion	predominance	in	
TBDM	patients.	 
	
C.6.3	 Degree	 of	 diabetes	 glycemic	 control	 and	 HIV	 immunosuppression	 influences	 chest	
radiograph	presentation	
	
We	found	that	TBDM	participants	with	poorer	glycemic	control	had	a	higher	proportion	of	
both	combined	and	isolated	LLF	involvement.	This	is	similar	to	a	study	conducted	in	Taipei,	
where	TBDM	participants	with	an	HbA1c	of	greater	than	9%	were	1,62	times	more	likely	to	
have	LLF	opacities	as	compared	to	TB	participants	without	DM(39).	There	is	also	a	suggestion	
that	DM	patients	with	poorer	glycemic	control	may	be	at	increased	risk	of	developing	TB	
disease(40).	This	is	of	particular	importance	in	our	setting	given	the	poor	degree	of	glycemic	
control	achieved	by	many	DM	patients	in	South	Africa	(41).		
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The	chest	radiographic	presentation	of	PTB	in	HIV-infected	patients	at	varying	degrees	of	
immunosuppression,	primarily	using	the	CD4	cell	count,	has	been	well	described(13,	34,	42,	
43).	Most	often	the	CD4	cell	count	is	used	as	a	marker	of	degree	of	immunosuppression.	
Studies	have	found	that	HIV-infected	patients	with	low	CD4	counts	were	more	likely	to	have	
atypical	radiographic	presentations	with	fewer	cavities,	increased	hilar	adenopathy	and	more	
diffuse	interstitial	infiltrates,	rather	than	the	typical	post-primary	pattern	of	apical	cavitation	
and	infiltrates.	Very	few	describe	the	distribution	of	lesions	by	CD4	cell	count	and	when	they	
do	the	description	is	often	limited	to	describing	lesions	in	either	upper	or	lower	zones,	but	
not	both.	Our	study	is	unique	as	we	have	described	the	changing	distribution	of	both	
cavitations	and	opacifications	within	the	lung	with	increasing	CD4	cell	count.	Whilst	our	study	
found	that	the	frequency	of	cavitation	decreased	as	CD4	count	declined	in	TBDMHIV	
participant,	this	was	not	observed	in	TBHIV	participants.	This	is	contrary	to	previous	findings	
and	could	be	attributed	to	omission	of	DM	status	from	HIV	chest	radiograph.		
	
C.6.4	Strengths	and	limitations	
	
This	is	one	of	the	few	studies	to	explore	the	effect	of	the	interaction	between	TB,	DM,	and	
HIV	on	chest	radiography,	on	a	relatively	large	sample	of	TB	patients	with	both	HIV	and	DM,	
in	a	setting	with	a	significant	burden	of	all	3	diseases.	As	the	risk	of	TB	is	increased	in	both	of	
these	conditions,	it	is	likely	that	there	will	be	an	increasing	proportion	of	patients,	especially	
in	the	study	setting,	that	have	both	these	diseases	and	TB.	It	is	important	to	have	a	better	
understanding	of	the	chest	radiographic	presentation	of	TB	in	these	patients	to	prevent	
misdiagnosis,	delayed	treatment,	and	unwarranted	morbidity	and	mortality.		
	
Our	study	had	a	number	of	limitations.	Of	the	potential	participants	from	the	parent	study,	
ninety	were	excluded	from	the	analysis	due	to	lack	of	chest	radiography,	potentially	biasing	
our	findings.	However,	the	omitted	participants	were	similar	to	the	study	sample	with	
regards	to	age,	sex,	and	TB	category	distributions,	as	well	as	median	HbA1c	and	CD4	cell	
count	values	(data	not	shown).	Therefore,	we	would	expect	minimal	variation	in	chest	
radiograph	findings	between	these	two	groups.	Diabetes	screening	was	conducted	at	TB	
diagnosis	which	may	have	resulted	in	over	diagnosis	of	DM	due	to	stress	induced	
hyperglycemia(44),	potentially	resulting	in	the	difference	in	radiological	presentation	
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between	DM	and	non-DM	participants	being	due	to	TB	disease	severity	rather	than	DM.	We	
were	limited	on	the	number	of	TBDM	participants	resulting	in	the	study	being	marginally	
underpowered,	with	our	sample	size	resulting	in	a	78%	power.	This	could	have	resulted	in	
some	of	our	results	not	being	statistically	significant,	especially	when	investigating	rarer	
radiological	findings.	Additionally,	as	we	extracted	the	participants’	CD4	count	retrospectively	
some	of	the	participant	data	was	missing,	reducing	our	ability	to	detect	statistically	significant	
differences	between	study	categories,	particularly	the	TBDMHIV	category,	when	stratifying	
by	CD4	count.	In	addition	to	CD4	count,	other	variables	that	may	influence	chest	radiographic	
presentation	that	were	not	collected	include	a	prior	history	of	trauma,	lung	or	heart	disease,	
exposure	to	chemicals	or	hazardous	working	environments	and	duration	and	extent	of	
smoking.	Finally,	there	was	a	risk	of	misclassification	of	radiographic	findings	due	to	inter-
reader	variability.	We	attempted	to	reduce	this	by	using	a	third	reader,	however	this	may	not	
have	eliminated	misclassification	bias	completely.		
	
C.7	Conclusion	
	
This	study	confirms	that	LLF	involvement,	particularly	cavitation	and	isolated	lesions,	on	the	
chest	radiograph	is	associated	with	DM	in	patients	with	PTB.	Co-infection	with	HIV	has	a	
significant	effect	on	this	relationship	and	results	in	the	modification	of	typical	TBDM	chest	
radiograph	patterns,	although	isolated	LLF	lesions	are	still	more	prominent	in	DM	with	or	
without	HIV-infection.	This	may	explain	some	of	the	varied	findings	in	previous	studies.	
Factors	which	may	alter	the	presentation	of	TBDM	radiography	include	HIV	status	(and	the	
degree	of	immunosuppression)	and	glycemic	control.	Therefore,	atypical	lesions	on	the	chest	
radiograph	of	patients	with	DM	and/or	HIV	should	alert	attending	clinicians	to	possible	active	
TB	disease	and	promote	microbiological	testing.	Additionally,	in	patients	with	proven	TB,	
atypical	lesions	could	prompt	the	screening	for	both	DM	and	HIV,	especially	in	high	DM	and	
HIV	burden	settings.	As	our	study	had	a	relatively	small	sample	of	TBDMHIV	patients,	further	
research	is	needed	to	fully	understand	how	DM	and	HIV	interact	to	influence	the	
presentation	of	PTB.	These	findings	should	inform	the	development	of	bidirectional	TB	
screening	algorithms	in	patients	with	DM,	with	or	without	HIV-infection,	and	highlights	the	
important	role	of	radiographic	examination	in	TB	screening	in	this	population.				
	
	 63	
C.8	Acknowledgements1	
NB	was	responsible	for	the	data	collection,	analysis	and	writing	of	the	manuscript.	RG	was	
responsible	for	study	coordination	and	staff	management.	VS	and	FO	assisted	in	chest	
radiograph	reading	and	reporting.	TO,	NL	and	RJW	were	responsible	for	design	of	parent	
study,	as	well	as	reviewing	and	editing	of	the	final	manuscript.		
	
C.9	Funding	
The	parent	study	which	supplied	the	data	for	this	work	was	supported	by	a	Wellcome	Trust	
Strategic	Funding	Clinical	Infectious	Disease	Research	Initiative	Fellowship	[Fund	number:	
412300	to	TO].	No	additional	funding	was	needed	for	this	study.		
	
C.10	Conflict	of	Interest2	
The	authors	report	no	potential	conflict	of	interest.	All	authors	have	submitted	the	ICMJE	
Form	for	Disclosure	of	Potential	Conflicts	of	Interest.	Conflicts	that	the	editors	consider	
relevant	to	the	content	of	the	manuscript	have	been	disclosed.	
1Authors	to	be	included	in	final	submission	to	Clinical	Infectious	Disease:	Natacha	Berkowitz	(NB),	Rene	
Goliath	(RG),	Vishesh	Sood	(VS),	Ferdie	Oompie	(FO),	Tolullah	Oni	(TO),	Naomi	Levitt	(NL)	and	Robert	J	
Wilkinson	(RJW).	
2For	the	purposes	of	this	dissertation	forms	have	not	been	submitted	to	Clinical	Infectious	Disease	
	
	 64	
C.11	References	
	
1.	 WHO.	Global	Tuberculosis	Report	2016.	
2.	 Jeon	CY,	Murray	MB.	Diabetes	mellitus	increases	the	risk	of	active	tuberculosis:	a	
systematic	review	of	13	observational	studies.	PLoS	Med.	2008;5(7):e152.	
3.	 Dillon	DG,	Gurdasani	D,	Riha	J,	Ekoru	K,	Asiki	G,	Mayanja	BN,	et	al.	Association	of	HIV	
and	ART	with	cardiometabolic	traits	in	sub-Saharan	Africa:	a	systematic	review	and	
meta-analysis.	Int	J	Epidemiol.	2013;42(6):1754-71.	
4.	 Guaraldi	G,	Orlando	G,	Zona	S,	Menozzi	M,	Carli	F,	Garlassi	E,	et	al.	Premature	age-
related	comorbidities	among	HIV-infected	persons	compared	with	the	general	
population.	Clin	Infect	Dis.	2011;53(11):1120-6.	
5.	 WHO.	Implementing	the	end	TB	strategy:	the	essentials.	2016.	
6.	 Cheng	S,	Chen	W,	Yang	Y,	Chu	P,	Liu	X,	Zhao	M,	et	al.	Effect	of	Diagnostic	and	
Treatment	Delay	on	the	Risk	of	Tuberculosis	Transmission	in	Shenzhen,	China:	An	
Observational	Cohort	Study,	1993-2010.	PLoS	One.	2013;8(6):e67516.	
7.	 Virenfeldt	J,	Rudolf	F,	Camara	C,	Furtado	A,	Gomes	V,	Aaby	P,	et	al.	Treatment	delay	
affects	clinical	severity	of	tuberculosis:	a	longitudinal	cohort	study.	BMJ	Open.	
2014;4(6):e004818.	
8.	 Cox	HS,	Mbhele	S,	Mohess	N,	Whitelaw	A,	Muller	O,	Zemanay	W,	et	al.	Impact	of	
Xpert	MTB/RIF	for	TB	diagnosis	in	a	primary	care	clinic	with	high	TB	and	HIV	
prevalence	in	South	Africa:	a	pragmatic	randomised	trial.	PLoS	Med.	
2014;11(11):e1001760.	
9.	 WHO.	Chest	radiography	in	tuberculosis	detection:	summary	of	current	WHO	
recommendations	and	guidance	on	programmatic	approaches.	Geneva;	2016.	
10.	 WHO.	Systematic	Screening	for	Pulmonary	Tuberculosis:	Principles	and	
Recommendations.	2013.	
11.	 Meintjes	G,	Wilkinson	RJ.	Undiagnosed	active	tuberculosis	in	HIV-infected	patients	
commencing	antiretroviral	therapy.	Clinical	infectious	diseases.	2010;51(7):830-2.	
12.	 Barnes	PF,	Bloch	AB,	Davidson	PT,	Snider	DE,	Jr.	Tuberculosis	in	patients	with	human	
immunodeficiency	virus	infection.	N	Engl	J	Med.	1991;324(23):1644-50.	
	 65	
13.	 Garcia	GF,	Moura	AS,	Ferreira	CS,	Rocha	MO.	Clinical	and	radiographic	features	of	
HIV-related	pulmonary	tuberculosis	according	to	the	level	of	immunosuppression.	Rev	
Soc	Bras	Med	Trop.	2007;40(6):622-6.	
14.	 San	KE,	Muhamad	M.	Pulmonary	Tuberculosis	in	HIV	Infection	:	The	Relationship	of	
the	Radiographic	Appearance	to	CD4	T-Lymphocytes	Count.	Malays	J	Med	Sci.	
2001;8(1):34-40.	
15.	 Perez-Guzman	C,	Torres-Cruz	A,	Villarreal-Velarde	H,	Salazar-Lezama	MA,	Vargas	MH.	
Atypical	radiological	images	of	pulmonary	tuberculosis	in	192	diabetic	patients:	a	
comparative	study.	Int	J	Tuberc	Lung	Dis.	2001;5(5):455-61.	
16.	 Wang	CS,	Yang	CJ,	Chen	HC,	Chuang	SH,	Chong	IW,	Hwang	JJ,	et	al.	Impact	of	type	2	
diabetes	on	manifestations	and	treatment	outcome	of	pulmonary	tuberculosis.	
Epidemiol	Infect.	2009;137(2):203-10.	
17.	 Marais	RM.	Diabetes	mellitus	in	black	and	coloured	tuberculosis	patients.	S	Afr	Med	J.	
1980;57(13):483-4.	
18.	 Shaikh	MA,	Singla	R,	Khan	NB,	Sharif	NS,	Saigh	MO.	Does	diabetes	alter	the	
radiological	presentation	of	pulmonary	tuberculosis.	Saudi	Med	J.	2003;24(3):278-81.	
19.	 Weaver	RA.	Unusual	radiographic	presentation	of	pulmonary	tuberculosis	in	diabetic	
patients.	Am	Rev	Respir	Dis.	1974;109(1):162-3.	
20.	 City	of	Cape	Town–2011	Census	Suburb	Khayelitsha.	2013	[Available	from:	
http://www.capetown.gov.za/en/stats/2011CensusSuburbs/2011_Census_CT_Suburb
_Khayelitsha_Profile.pdf.	
21.	 Medicin	Sans	Frontieres.	Khayelitsha	2001-2011	activity	report.	10	years	of	HIV/TB	
care	at	the	primary	health	care	level.	
22.	 Western	Cape	Department	of	Health.	Western	Cape	Antenatal	HIV	Prevalence	Survey	
2011..	
23.	 Peer	N,	Steyn	K,	Lombard	C,	Lambert	EV,	Vythilingum	B,	Levitt	NS.	Rising	diabetes	
prevalence	among	urban-dwelling	black	South	Africans.	PLoS	One.	2012;7(9):e43336.	
24.	 American	Diabetes	Association.	Diagnosis	and	classification	of	diabetes	mellitus.	
Diabetes	Care.	2014;37	Suppl	1:S81-90.	
25.	 WHO.	The	STEPS	Instrument	and	Support	Materials		[Available	from:	
http://www.who.int/chp/steps/instrument/en/.	
	 66	
26.	 Den	Boon	S,	Bateman	ED,	Enarson	DA,	Borgdorff	MW,	Verver	S,	Lombard	CJ,	et	al.	
Development	and	evaluation	of	a	new	chest	radiograph	reading	and	recording	system	
for	epidemiological	surveys	of	tuberculosis	and	lung	disease.	Int	J	Tuberc	Lung	Dis.	
2005;9(10):1088-96.	
27.	 National	Department	of	Health.	National		Consolidated	Guidelines	for	the	Prevention	
of	Mother-	to-	Child	Transmission	of	HIV	(PMTCT)	and	the	management	of	HIV	in	
Children,	Adolescents	and	Adults	2015	April	2015.	
28.	 Chiang	CY,	Lee	JJ,	Chien	ST,	Enarson	DA,	Chang	YC,	Chen	YT,	et	al.	Glycemic	control	
and	radiographic	manifestations	of	tuberculosis	in	diabetic	patients.	PLoS	One.	
2014;9(4):e93397.	
29.	 Angthong	W,	Angthong	C,	Varavithya	V.	Pretreatment	and	posttreatment	radiography	
in	patients	with	pulmonary	tuberculosis	with	and	without	human	immunodeficiency	
virus	infection.	Jpn	J	Radiol.	2011;29(8):554-62.	
30.	 Batungwanayo	J,	Taelman	H,	Dhote	R,	Bogaerts	J,	Allen	S,	Van	de	Perre	P.	Pulmonary	
tuberculosis	in	Kigali,	Rwanda.	Impact	of	human	immunodeficiency	virus	infection	on	
clinical	and	radiographic	presentation.	Am	Rev	Respir	Dis.	1992;146(1):53-6.	
31.	 Mlika-Cabanne	N,	Brauner	M,	Mugusi	F,	Grenier	P,	Daley	C,	Mbaga	I,	et	al.	
Radiographic	abnormalities	in	tuberculosis	and	risk	of	coexisting	human	
immunodeficiency	virus	infection.	Results	from	Dar-es-Salaam,	Tanzania,	and	scoring	
system.	Am	J	Respir	Crit	Care	Med.	1995;152(2):786-93.	
32.	 Pozniak	AL,	MacLeod	GA,	Ndlovu	D,	Ross	E,	Mahari	M,	Weinberg	J.	Clinical	and	chest	
radiographic	features	of	tuberculosis	associated	with	human	immunodeficiency	virus	
in	Zimbabwe.	Am	J	Respir	Crit	Care	Med.	1995;152(5	Pt	1):1558-61.	
33.	 Aderaye	G,	Bruchfeld	J,	Assefa	G,	Feleke	D,	Kallenius	G,	Baat	M,	et	al.	The	relationship	
between	disease	pattern	and	disease	burden	by	chest	radiography,	M.	tuberculosis	
Load,	and	HIV	status	in	patients	with	pulmonary	tuberculosis	in	Addis	Ababa.	
Infection.	2004;32(6):333-8.	
34.	 Kisembo	HN,	Boon	SD,	Davis	JL,	Okello	R,	Worodria	W,	Cattamanchi	A,	et	al.	Chest	
radiographic	findings	of	pulmonary	tuberculosis	in	severely	immunocompromised	
patients	with	the	human	immunodeficiency	virus.	Br	J	Radiol.	2012;85(1014):e130-9.	
	 67	
35.	 al-Wabel	AH,	Teklu	B,	Mahfouz	AA,	al-Ghamdi	AS,	el-Amin	OB,	Khan	AS.	
Symptomatology	and	chest	roentgenographic	changes	of	pulmonary	tuberculosis	
among	diabetics.	East	Afr	Med	J.	1997;74(2):62-4.	
36.	 Gil-Santana	L,	Almeida-Junior	JL,	Oliveira	CA,	Hickson	LS,	Daltro	C,	Castro	S,	et	al.	
Diabetes	Is	Associated	with	Worse	Clinical	Presentation	in	Tuberculosis	Patients	from	
Brazil:	A	Retrospective	Cohort	Study.	PLoS	One.	2016;11(1):e0146876.	
37.	 Jain	N,	Madan	A,	Sharma	T,	Purohit	S,	Agrawal	K,	Agnihotri	S,	et	al.	Diabetic	
tuberculosis:	a	changing	pattern.	Lung	India.	1985;3(1):11.	
38.	 Wang	JY,	Lee	LN,	Hsueh	PR.	Factors	changing	the	manifestation	of	pulmonary	
tuberculosis.	Int	J	Tuberc	Lung	Dis.	2005;9(7):777-83.	
39.	 Chiang	C-Y,	Lee	J-J,	Chien	S-T,	Enarson	DA,	Chang	Y-C,	Chen	Y-T,	et	al.	Glycemic	
control	and	radiographic	manifestations	of	tuberculosis	in	diabetic	patients.	PloS	one.	
2014;9(4).	
40.	 Baker	MA,	Lin	H-H,	Chang	H-Y,	Murray	MB.	The	risk	of	tuberculosis	disease	among	
persons	with	diabetes	mellitus:	a	prospective	cohort	study.	Clinical	infectious	
diseases.	2012:cir939.	
41.	 Folb	N,	Timmerman	V,	Levitt	NS,	Steyn	K,	Bachmann	MO,	Lund	C,	et	al.	
Multimorbidity,	control	and	treatment	of	non-communicable	diseases	among	primary	
healthcare	attenders	in	the	Western	Cape,	South	Africa.	SAMJ:	South	African	Medical	
Journal.	2015;105(8):642-7.	
42.	 da	Silva	RM,	da	Rosa	L,	Lemos	RN.	Radiographic	alterations	in	patients	presenting	
human	immunodeficiency	virus/tuberculosis	coinfection:	correlation	with	CD4+	T	cell	
counts.	J	Bras	Pneumol.	2006;32(3):228-33.	
43.	 Keiper	MD,	Beumont	M,	Elshami	A,	Langlotz	CP,	Miller	WT,	Jr.	CD4	T	lymphocyte	
count	and	the	radiographic	presentation	of	pulmonary	tuberculosis.	A	study	of	the	
relationship	between	these	factors	in	patients	with	human	immunodeficiency	virus	
infection.	Chest.	1995;107(1):74-80.	
44.	 Boillat-Blanco	N,	Ramaiya	KL,	Mganga	M,	Minja	LT,	Bovet	P,	Schindler	C,	et	al.	
Transient	Hyperglycemia	in	Patients	With	Tuberculosis	in	Tanzania:	Implications	for	
Diabetes	Screening	Algorithms.	J	Infect	Dis.	2016;213(7):1163-72.	
	
	 	
	 68	
Part	D	Appendices	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 69	
D.1	Protocol	for	parent	study	
OVERALL RESEARCH OBJECTIVE  
The main aim of this study is to investigate the incremental yield and best screening algorithms for 
diabetes mellitus (DM) and tuberculosis (TB) among a) newly diagnosed TB patients and b) patients 
attending diabetic clinics, respectively.  
Specific aims:  
•  To assess the prevalence of DM among Cases  
•  To evaluate the best performing algorithms to diagnose DM in Cases  
•  To measure the prevalence of TB among diabetes patients   
BACKGROUND  
TB remains a leading cause of death globally, with an estimated 8.8 million new cases reported every 
year, threatening the goal of global TB elimination by year 2050 (1). Tackling this challenge will 
require not only improvements in diagnostic and treatment services, but identification and reduction of 
risk factors that increase susceptibility for TB. Medical conditions that impair immune function, such 
as malnutrition, alcoholism or HIV co-susceptibility for TB. Medical conditions that impair immune 
function, such as malnutrition, alcoholism or HIV co-infection, can increase the likelihood of infection 
or reactivation of latent TB. Increasing evidence suggests that DM is also a significant risk factor for 
TB. In a recent systematic review, the relative risk for TB in diabetic patients was 3.1 (2). The strength 
of this link was influenced by geographic/ethnic differences, and  
young people were at particularly high risk; in India, DM is thought to be associated with nearly 15% 
of pulmonary Cases (3). However, these studies had a number of limitations. In particular, very few 
were carried out in low-income countries, with none in Africa, raising uncertainty about the strength of 
DM-TB association and benefit of bi-directional screening for DM and TB in these settings with high 
TB/HIV prevalence and AN increasing burden of DM. Practical guidance on when to suspect, and 
how best to diagnose, diabetes in TB patients, and how to confirm or exclude it are lacking. The 
World Health Organisation recommends HbA1c as a diagnostic test for diabetes with a cut-off value 
of 6.5% (4). However, less clear is the diagnostic value of results below the WHO cut-off (there is an 
argument for population-specific cut-off values). A study conducted on a population of mixed-ancestry 
in Cape Town showed that this cut-off value was sub-optimal (erasmus). Furthermore, it is not known 
how the diagnostic performance of the cut-off is affected by acute illness, such as TB. A point of care 
HbA1c test could make diabetes screening more effective and potentially more affordable. A study 
comparing POC devices found that only Afinion and DCA Vantage met the diagnostic performance 
criteria (6). There are also insufficient data on which to base TB screening guidelines for diabetic 
patients.  
The growing epidemic of diabetes as a threat to TB control  
While 95% of patients with TB live in the low- and middle-income countries, 70% of patients with DM 
also live in these same countries. It is estimated that, worldwide in 2010, there were 285 million 
people with DM, and the number predicted to rise to 438 million by 2030, making DM one of the most 
common NCDs globally (7). The majority of this increase will occur in developing countries where TB 
remains endemic. Diabetes on this scale is likely to pose another threat for global TB control. The 
potential public health and clinical importance of this seems to have been largely ignored until 
recently. Recent joint consultations by International Union Against Tuberculosis and Lung Disease, 
the World Diabetes Foundation and the World Health Organization emphasised the urgent need for 
research in this area (10). There is also a paucity of data on whether DM is associated with a high 
prevalence of subclinical TB among patients attending diabetic clinics, as observed in HIV-1 co-
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infected persons (13). This has major importance when considering TB screening strategies, with 
potential for amplification by transmission within diabetic clinics and also potentially serious 
consequences of false-negative TB screening. Research is therefore required to develop appropriate 
and evidence-based guidelines for TB screening among persons with DM.  
Diabetes, HIV and TB in South Africa and the Western Cape  
South Africa is among the 22 high TB burden countries globally, and also has the highest urban: rural 
ratio in sub-Saharan Africa, with 62% of the population being urban dwellers (17). Urbanisation, in 
addition to rapid epidemiological and demographic transition has resulted in a rising burden of NCDs. 
The global burden of disease study demonstrated that in Southern Africa, while HIV and TB rank first 
and 4th in the top ten causes of morbidity, 50% of the causes of morbidity are non-communicable; 
diabetes is ranked 7th. A community survey conducted in 2008/9 from Cape Town townships showed 
a DM prevalence of 13.1% (95% CI: 11.0- 15.1) (26).  
Mortality rates from NCDs are also increasing; diabetes was the 6th leading causes of mortality in 
South Africa in 2010. In the Western Cape, the province within which Cape Town is located, TB and 
DM are the top 2 causes of mortality. Against this background, the prevalence of HIV, the strongest 
known risk factor for TB, remains high, with 70% of TB cases being HIV-infected in Khayelitsha  
PLAN OF INVESTIGATION  
Setting and study population 
The study will be conducted in Khayelitsha, reputed to be the fastest growing township in South 
Africa. Khayelitsha is located 30km from Cape Town with a population of over 500,000 predominantly 
black Africans, HIV antenatal prevalence of 28% and a TB case-notification rate of >1600/100,000 
(27). The largest TB clinic in Khayelitsha is Ubuntu clinic. A survey by the Department of Health 
reported 1187 newly registered TB cases were diagnosed at Ubuntu clinic in 2011.  
Study design  
DM Screen in TB patients  
We will recruit consecutive TB cases at Ubuntu clinic, prior to initiation of TB treatment. We will record 
demographic, medical and drug history, HIV status and (if positive) date of initiation of ART, regimen, 
and CD4 count, as well as clinical, microscopic and radiological characteristics of TB at diagnosis. In 
addition we will document other risk factors for diabetes, such as family history, body mass index 
(BMI), and waist circumference. Before starting TB chemotherapy blood samples will be collected to 
measure fasting blood glucose and oral glucose tolerance test, and HbA1c performed using Afinion, a 
validated HbA1c Point of care test. Patients will be considered to be diabetic if 1) the diagnosis is 
known at presentation, 2) they are taking oral hypoglycaemic therapy and/or insulin or 3) as per case 
definitions. Previous studies have suggested that it may be more reliable to screen for diabetes later 
in the course of TB treatment rather than at the start (11), because inflammation/cytokine stimulation 
associated with active TB may elevate blood glucose levels resulting in false positive diabetes 
diagnoses if tests are performed too early. We will, therefore, repeat fasting blood glucose and HbA1c 
tests after 2 months of TB treatment. Patients with a new diagnosis will be referred to the DM clinic for 
standard care. HIV testing is offered routinely to all patients with TB.  
TB screen in diabetic patients  
We will recruit consecutive diabetes patients presenting to the primary care diabetes clinic at 
Khayelitsha day hospital. A TB screen will be performed as per case definition. We will also record 
demographic, medical and drug history, previous TB and TB contact history, as well as HbA1c to 
measure glycaemic control at the time of recruitment.  
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Subclinical TB disease Smear microscopy positive for acid fast bacilli Isolation  
Outcome measures  
Primary outcome 
 
      • The best performing screening algorithm to diagnose DM in TB patients  
Secondary outcomes  
•  Accuracy of established intensified TB case-finding strategies among diabetics  
•  Prevalence of diabetes in TB patients  
•  Prevalence of TB in diabetics, including subclinical TB disease  
•  Effect of diabetes on TB clinical presentation (number and duration of pulmonary TB 
symptoms, TB  
sputum smear and microscopy results, CXR findings, non-pulmonary manifestation of disease) and/or 
treatment outcomes of TB (2 month TB sputum clearance, completion and cure rates)  
Sample size and power calculations  
Assuming a DM prevalence of 24% in TB patients (based on a TB/DM risk ratio of 2 and DM 
prevalence in the general population of 12%), in order to have 80% statistical power and a screening 
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tool sensitivity of 60%, a sample size of 1537 TB cases is required in Malawi and South Africa 
respectively. This sample size will provide sufficient power to define and investigate different potential 
DM screening algorithms in TB patients.  
For the TB prevalence in DM patients study, a sample size of 457 diabetic patients is required, 
assuming TB prevalence of 5% and at 2% precision.  
Statistical analysis plan  
The prevalence of diabetes and TB will be based on the respective gold standard diagnostic tests. We 
will calculate the sensitivity, specificity, positive and negative predictive values of the screening tools 
to diagnose  
DM in TB cases, and TB in DM patients, using OGTT and TB culture gold standards, respectively. 
Among TB cases, risk factors associated with DM will be analysed using logistic regression. The 
model will be built manually with nested models compared using the likelihood ratio test. The Akaike’s 
Information Criterion (AIC) will be used to compare non-nested models with a significantly lower AIC 
(>10%) indicating an improved model. In addition, outlying and influential observations will be 
identified and potential effect modification assessed using interaction variables.  
To develop and evaluate a DM screening algorithm in TB cases, based on symptom screening, HIV 
status, ART, age, sex, BMI, waist circumference, and DM family history. Multivariable logistic 
regression analysis will then be performed to develop diagnostic models for DM using OGTT findings 
as the gold standard. A reduced clinical model without additional investigations will first be derived. 
These tests will then be added singly to the reduced clinical model and then simultaneously to explore 
the added predictive value of a single test and of combined tests, respectively. The ability of a 
multivariable model to discriminate persons with DM from those without will be assessed using 
Receiver Operator Characteristic curve and Area Under the Curve analysis. Significance testing will 
be done using a combination of two-sided p-values (p<0.05) and 95% confidence intervals. All data 
will be analysed using STATA 12.0 (StataCorp, College Station, TX, USA)  
Ethical considerations  
This study has received ethics approval from the University of Cape Town Human Ethics committee 
(HREC Ref: 403/2011). A written consent will be obtained from all participants who will be given 
detailed explanation of the study. An information sheet will be available both in English and Xhosa.  
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Anticipated overall outputs and impacts  
This study performed at such an important time, with respect to the emerging diabetes epidemic in 
sub- Saharan Africa, will provide an invaluable set of data to document the strength of association 
between diabetes and TB and its clinical/public health impact. Data of this quality does not exist in the 
current literature on the link between TB and diabetes in sub-Sahara Africa; hence we expect this 
study to produce a series of high quality publications. Additionally, the study is designed to raise 
further research questions and provide some of the ground work needed, for example to determine 1) 
optimal screening models 2) whether diabetes influences recurrence of TB or anti-tuberculosis drug 
resistance 3) the need to develop randomised controlled trials of efficacy of interventions, such as TB 
chemoprophylaxis in people with diabetes, to improve outcomes of both diseases.  
 
Contingency plans  
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Participant Study Number: DBSN- __ _ 
Step 1 Demographic Information **(start on page 8)** 
Date Response Code 
13 Interviewer name 114 
14 Date dd mmm yyyy 115 
Baseline TB group assignment (as per log book) 
TB Case: TB diagnosed on smear/XperVculture PLUS TB treatment 
to be commenced 
15 TB case 1 116 TB Control: Symptoms resolved PLUS TB investigations negative to 
date PLUS no TB treatment commenced TB control 2 
If excluded, do not proceed 
EXPANDED: Demographic Information 
No formal schooling 1 
Started primary school but did not 2 
complete 
What is the highest level of education you have Primary school completed 3 
completed? Started high school but did not 
16 complete 4 cs 
High school completed 5 
College/University completed 6 
Post graduate degree 7 
Refused 88 
Never married 1 
Currently married 2 
Separated 3 
17 What is your marital status? Divorced 4 Cl 
Widowed 5 
Co-habiting 6 
Refused 88 
Government employee 1 
Non-government employee 2 
Which of the following best describes your main work Self-employed 3 
status over the past 12 months? Non-paid 4 
Student 5 
18 Homemaker 6 cs 
Retired 7 
Unemployed (able to work) 8 
Unemployed (unable to work) 9 
Unemployed (receiving grants) 10 
Refused 88 
19 How many people older than 18 years, including Number of people C9 yourself, live in your household? 
Per week C10a 
I I I I I I I I 
Taking the past year, can you tell me what the average OR per month C10b 
income of the household (induding grants) have been? I I I I I I I I 
20 (RECORD ONLY ONE, NOT ALL 3) 
OR per year C10c 
I I I I I I I I 
Refused C10d 
88 
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Participant Study Number: DBSN-
Step 2 Behavioural Measurements 
CORE: Tobacco Use 
Now I am going to ask you some questions about various health behaviours. This includes things like smoking, drinking alcohol, eating fruits 
and veoetables and ohvsical activitv. Let's start with tobacco. 
Question Response Code 
Do you currently smoke any tobacco products, such Yes 1 
21 as cigarettes, cigars or pipes? T1 
No 2 If No, go to q26 
Yes 1 
22 Do you currently smoke tobaoco products daily? T2 
No 2 If No, go to q26 
How old were you .Alen you first started smoking Age (years) T3 23 dai y? Don't know 77 L..l...J If Known, oo to 025 
Do you remember how long ago it was? In Years L..l...J T4a 
24 (RECORD ONLY 1, NOT ALL 3) OR in Months L..l...J T4b 
Don't know 77 
OR in Weeks T4c L..l...J 
Manufactured cigarettes L..l...J T5a 
On average, how many of the followi,g do you smoke Han~led cigarettes L..l...J T5b 
each day? 
Pipes full of tobacco T5c L..l...J 
25 (RECORD FOR EACH TYPE) 
Don't Know 77 
Cigars L..l...J T5d 
Other L..l...J T5e 
Other (please specify): T5other 
EXPANDED: Tobacco Use 
Question Response Code 
Yes 1 
26 In the past, did you ever smoke daily? T6 
No 2 If no, go to q29 
27 How old were you when you s.topped smoking daily? 
Age [years) 
T7 
Don't Know 77 L..l...J If known, ao to a29 
How long ago did you stop smoking daily? Years ago L..l...J T8a 
28 (RECORD ONLY 1, NOT ALL 3) OR Months ago L..l...J T8b 
DonTKnow 77 OR Weeks ago T8c L..l...J 
·- -
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Participant Study Number: DBSN-
CORE: Diet 
The next questions ask about the fruits and vegetables that you usually eal As you answer these questions please think of a typical week in 
the last year. 
Question Response Code 
37 
In a typical week, on how many days do you eat fruit? Number of days 0 1 0on, Know77 L...L.J If Zero days, go to q39 
38 How many servings of trua do you eat on one of those Number of servin~s D2 days? 0on, Know77 L...L.J 
39 In a typical week, on how many days do you Number of days D3 eat vegetables? 0on, Know77 L...L.J If Zero davs, qo to C/41 
40 How many servings of vegetables do you eat on one of 
Number of servings D4 
those days? Don't know 77 L...L.J 
EXPANDED: Diet 
Vegetable / fish/ olive oil 1 
Animal fats 2 
Butter or ghee 3 
Whal type of oil or fat is most often used for meal Margarine 4 D5 
41 preparation il your household? Other 5 If Other, r,o to 05other 
None in particular 6 
None used 7 
Don't know 77 
Other D5other 
On average, how ma:iy meals per week do you eat that Number 
42 were nol ptepared al home? By meal, I mean breakfast, D6 
lunch and dinner. Don't know 77 L...L.J 
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Participant Study Number: DBSN-
CORE: Physical Activity 
Next I am going to ask you about the time you spend doing different types of physical activity in a typical week. Please answer these questions 
even if you do not consider yourself to be a physically active person. 
Think first about the time you spend doing work. Think of work as the things that you have to do such as paid or unpaid work, study/training, 
household chores, harvesting food/crops, fishing or hunting for food, seeking employment. In answering the following questions 'vigorous-
intensity activities' are activities that require hard physical effort and cause large increases in breathing or heart rate, 'moderate-intensity 
activities' are activities that reouire moderate ohvsical effort and cause small increases in breathina or heart rate. 
Question Response Code 
Work 
Does your work involve vigorous-<nlensity activity that Yes 1 
43 causes large inaeases in breathing ()( heart rate like P1 canying ()( lifting heavy loads, <figging or construction 
""'* for al least 10 minutes continuously? No 2 If No, go to q46 
44 In a typical week, on how many days do you do Number of days P2 vigorous-intensity activities as part of your work? L...l.....J 
45 How much time do you spend doing vig()(OUs-<nlensity P3 activities al work on a typical day? Hours : minutes (a-b) 
hrs mins 
Does your work involve moderate-intensity activity that Yes 1 
46 causes small inaeases in breathing or heart rate such P4 as brisk walking or canying light loads for al least 10 
minutes continuously? No 2 If No, go to q49 
47 In a typical week, on how many days do you do Number of days P5 moderate-intensity activities as part of your work? 
How much time do you spend doing moderate-intensity P6 48 activities al work on a typical day? Hours : minutes (a-b) 
hrs mins 
Travel to and from places 
The next questions exclude the physical activities at work that you have already mentioned. 
Now I would like to ask you about the usual way you travel to and from places. For example to work, for shopping, to market. to place of 
worship. 
Do you walk ()( use a bicycle for al least 10 minutes Yes 1 49 P7 continuously lo get lo and from places? No 2 If No, go to q52 
In a typical week, on how many days do you walk ()( 
PB 50 bicycle f()( at least 10 minutes continuously to gel to Number of days 
and from places? 
51 How much time do you spend walking ()( bicycling for P9 travel on a typical day? Hours : minutes (a-b) 
hrs mins 
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Participant Study Number: DBSN-
CORE: Physical Activity, Continued 
Question Response Code 
Recreational activities 
The next questions exclude the work and transport activities that you have already mentioned. 
Now I would like to ask you about sports, fitness and recreational activities (leisure). 
Do you do any vigorous-intensity sports, fi1ness or Yes 1 recreational (leisure) activities that cause large 
52 increases in breathing or heart rate like running or P10 
foolbaU for at least 10 minutes continuously? 
No 2 If No, go to q55 
In a typical week, on how many days do you do 
P11 53 vigorous-intensity sports, fi!ness or reaeational Number of days 
(leisure) activities? L..l...J 
How much time do you spend doing vigorous-intensity P12 54 sports, fi!ness or recreational activities on a typical day? Hours : minutes (a-b) 
hrs mins 
Do you do any moderate-intensity sports, fi1ness or Yes 1 
recreational (leisure) activities that cause a small 
55 increase in breathing or heari rate such as brisk P13 
walking, cycling, swimming, soflba/1 for al least 10 
minutes continuously? No 2 If No, go to q58 
In a typical week, on how many days do you do 
P14 56 moderate-intensity sports, filr,ess or reaeational Number of days 
(leisure) activities? L..l...J 
How much time do you spend doing moderate-intensity P15 57 sports, fi!ness or recreational (leisure) activities on a Hours : minutes (a-b) typical day? hrs mins 
Sedentary behaviour 
The following question is about sitting or reclining at work, at home, getting to and from places, or with friends including time spent sitting at a 
desk, silting with friends, traveling in car, bus, train, reading, playing cards or watching television, but do not include time spent sleeping. 
58 How much time do you usually spend sittilg or reclining P16 
on a typical day? Hours : milutes (a-b) 
hrs mins 
A NNEX RE T b d u 0 ecompele ff by sla member 
DIABETES HISTORY 
Question Response Code 
Yes 1 
59 Any ramay histo,y of di,,bctcs? R1 
No 2 
Have you ever had diabetes during ~nancy Yes 1 60 R2 (gestational diabetes)? No 2 
	 84	
Participant Study Number: DBSN-
Step 3 Biochemical Measurements 
CORE: Blood Glucose and HbA1c 
Quest ion Response Code 
61 Blood preSSll'e I 
--- ---
J1 
During the past ~12 hours have you had anything to Yes 1 
eat eo< drink, other than water? 
62 
If yes, ccmplete STEPS 1 and 2, and re-schedule 
B1 appointment for blood tests: No 2 
Date: 
dd mmm WW 
Fasting blood glucose and HbA1c HOll'S : minutes L..l...J L.L.J 
63 B5 
Fasting glucose mmol/l I I I I L.J 
HbA1c% L..l...J L.L.J 
64 Oral glucose tolerance lest 
HOll'S : minutes L..l...J L.L.J B6 
2 hour glucose mmol/l I I I I L.J 
CORE: B!lood Lipids 
65 
Total cholesterol 
B8 mmol/l L..l...J L.L.J 
EXPANDED: Triglycerides and HDL Cholesterol 
66 
Triglycerides 
mmot/1 L..l...J L..l...J B10 
67 
HDl. Cholesterol 
mmol/1 L.J L.L.J B1 1 
Return Date Response Code 
68 
Appointment dale for diabetes and cholesterol results 
812 (1 week) dd mmm yyyy 
69 
Appointment dale for completion of step 4 
813 (2months) dd mmm yyyy 
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D.4	Chest	Radiograph	Report	Form	
	
	
Date	of	CXR	(dd/mmm/yyyy)	 	 	 	 										Date	of	Reading	(dd/mmm/yyyy)	
	
	
	
	
CXR	Reader		 	 	Reader	1				 	Reader	2				 	Reader	3				 	Consensus	
	
CXR	Views		 	 	PA				 	Lateral	 	
	
	
	
1.	Parenchymal	abnormalities	 	 	Yes	 	 	No	
	
Location	of	parenchymal	abnormalities	 	 	Left	 	 	Right	 	 	Bilateral	
	
	
	
Airspace	Opacities	present		 	Yes	 	 	No	 	 	Maybe	 	Not	visible	
	
Location	of	Airspace	Opacities	 	 	RUL	 	 	LUL	
	 	 	 	 	 	RML	
	 	 	 	 	 	RLL	 	 	LL	
	
Opacities	calcified	 	 	 	 	Yes	 	 	No	
	
	
	
Cavities	present	 	 	 	Yes	 	 	No	 	 	Maybe	 	Not	visible	
	
Location	of	Cavities	 	 	 	RUL	 	 	LUL	
	 	 	 	 	 	RML	
	 	 	 	 	 	RLL	 	 	LL	
	
	
	
Bilateral	miliary	nodules	 	 	Yes	 	 	No	 	 	Maybe	 	Not	visible	
	
	
	
2.	Pleural	effusion	(abnormalities)	 	Yes	 	 	No	 	 	Maybe	 	Not	visible	
	 	 	 	 	 	
Location	of	pleural	effusion	 	 	 	Left	 	 	Right	 	 	Bilateral	
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3.	Lymphadenopathy	 	 	 	Yes	 	 	No	 	 	Maybe	 	Not	
visible	
	
Location	of	lymphadenopathy	 	 	 	Right	hilar	 	 	Left	hilar	 	 	Bilateral	
	 	 	 	 	 	Right	mediastinal	 	Left	mediastinal	
	
	
	
4.	Cardio	thoracic	ratio	increased	(>0.5)		 	Yes	 	 	No	
	
	
RMCD																					.	 							cm	 	 LMCD																																.	 	 cm	 	 MTD				 															.	 	 cm	
	
	
RMCD	=	Right	Max.	Cardiac	Diameter	 	 LMCD	=	Left	Max.	Cardiac	Diameter	 	 	 MTC	=	Max.	Thoracic	Diameter	
	
	
	
5.	Overall	assessment:	CXR	normal?		 	Yes	 	 	No	
	
	
TB-related	CXR	findings?	 	 	 	 	Yes	 	 	No	
	
	
Activity	of	TB	findings	 	 	 	 	Active	 	 	Inactive	 	N/A	
	
	
	
8.	Technical	aspects	
	
PA	 	 	Acceptable	 												 	Poor	but	readable	 														 	Not	acceptable	 	 	No	readable	
	
Lateral	 	 	Acceptable				 												 	Poor	but	readable	 														 	Not	acceptable	 	 	No	readable	
	
	
	
9.	Comments:	
_________________________________________________________________________________________________________________
_________________________________________________________________________________________________________________
_________________________________________________________________________________________________________________
_________________________________________________________________________________________________________________
_____________________________________________________	
	
	
	
______________________________________________________________	
Initials	and	date	of	doctor	completing	the	task	above	
	
	
	
______________________________________________________________	
Database	Capture:	Initials	and	date	of	person	completing	data	entry	
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D.5	Informed	Consent	for	parent	study	(English	Version)	
	
UNIVERSITY	OF	CAPE	TOWN	
	 	
	
 
Room S3.03 
Institute of Infectious Diseases and Molecular Medicine 
Faculty of Health Sciences 
Observatory 7925 
South Africa 
Tel: +27 (0)21 406 6079 
 
	
	
Epidemiology of Diabetes, TB and HIV co-infection in a high HIV/TB burden 
setting 
 
INFORMED CONSENT and INFORMATION FORM 
 
My name is _______________________ 
I wish to invite you to participate in a study that is trying to assess the interaction between 
tuberculosis (TB), HIV and Diabetes. This study is being run by the Institute of Infectious Diseases 
and Molecular Medicine at the University of Cape Town. Dr Tolullah Oni is the Principal Investigator. 
 
Firstly, I wish to explain to you why this research is being done: 
 
TB is a disease that is seen very commonly in Cape Town and, indeed, in most of South Africa. It is 
caused by bacteria that people breathe in and the infection results in cough, fevers and weight loss. 
The disease is more common, and can be more severe, in patients with HIV infection. 
 
Diabetes is a disease caused by the body’s inability to control sugar levels. This disease is becoming 
increasingly more common worldwide and in South Africa due to reduced exercise and increasing 
obesity. Previous studies have shown that like HIV, diabetes increases the risk of TB.  But there are a 
few things we still do not know: 
1. We do not know how much diabetes (and risk factors such as high cholesterol) there is in this 
setting.  
2. We also do not know if the increasing levels of diabetes are contributing significantly to the 
TB epidemic, and  
3. Although we know that HIV increases the risk of TB, we do not know if having HIV and 
diabetes further increases the TB risk. In other words, we do not know if a person with HIV 
and diabetes is at higher risk of TB than a person with HIV and no diabetes. 
 
In addition, we know that low  vitamin D levels increase the risk of TB. We also know that many 
people in Cape Town have very low levels of vitamin D. Therefore we also wish to measure your 
vitamin D level and see how this affects the risk of TB and recovery from TB in TB patients. 
 
We request your participation in this study either because you are being investigated for TB, because 
you have been diagnosed with diabetes, or because you have recently undergone HIV counselling 
and testing (HCT).  
 
As part of this study, we will check your blood for HIV and check your sputum (spit) for TB.  We will 
also check you for Diabetes using the following tests: 
We will ask you to come again before eating or drinking anything and check your sugar level that 
morning and 2 hours later after giving you a sugary drink. You must not eat or drink anything else during 
these 2 hours. We will also do an HbA1c test, a blood test for diabetes and check your blood cholesterol 
level. We will pay 30 Rand travel expenses for this purpose. 
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We will also take blood to measure your vitamin D level. If we diagnose HIV, we will give you a 
referral letter to take to any HIV clinic of your choice where baseline bloods will be done and your 
eligibility for antiretroviral therapy can be assessed. If TB is found, we will also give you a letter to take 
to your nearest TB clinic as it will be important to start TB treatment as soon as possible. If diabetes is 
diagnosed, we will write a referral letter for you and advise you of your nearest diabetes club where 
you can be started on appropriate treatment and receive regular advice on diet and lifestyle. If high 
cholesterol is diagnosed, we will write a referral letter to your ARV clinic or day hospital for further 
management. 
 
It is entirely up to you to decide whether or not to take part in this study. If you do decide to take part, you 
will be asked to sign this consent form. We will then request you to provide us with an extra blood sample 
(15ml) that can be taken at the same time as your normal blood tests and may perform a Chest X Ray. 
 
Although blood testing very rarely causes problems, if anything goes wrong the University provides 
insurance to cover this possibility. This study will also be monitored by the Research Ethics 
Committee of the University of Cape Town. Their job is to ensure your safety and protect you during 
the study. 
 
The decision to participate is entirely your own. IF YOU DECIDE NOT TO PARTICIPATE, YOUR 
TREATMENT WILL NOT BE DIASDVANTAGED IN ANY WAY. In addition, at any point during the 
study you are free to withdraw without telling us why. 
 
Throughout the study your privacy will be maintained and nobody other than the doctors and nurses 
looking after you will know that you are participating. Samples will be labelled with code numbers and 
hence the laboratory staff will not know your identity. When the results of the study become available, 
names of the participating patients will not be included. 
 
Do you have any questions? During the study you may contact either the Human Research Ethics 
Committee (021 406 6492) or Dr Tolullah Oni (021 406 6079) if you have further questions. Please 
remember that Dr Oni will not be directly responsible for your medical care which will be conducted by 
your regular doctors and nurses. 
 
Consent to participate in the study: 
I have read the above / have had the above read to me. I have had the opportunity to discuss the 
study with  _______________________ and have also had the opportunity to ask any questions. I 
consent to  
take part in this study: 
 
Name __________________ 
 
Signature ____________________ 
 
Date _____________________ 
 
Name of Staff member consenting __________________ 
 
Signature _______________ 
 
Date ______________________  
 
Witness (if participant is illiterate) 
 
Name  _____________________ 
 
Signature ___________________ Date  ____________________ 
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D.6	Detailed	statistical	analysis	
	
Descriptive	statistics	and	univariate	analysis:	
Participants	were	stratified	by	TB	category,	that	is,	participants	with	only	TB,	TB	and	HIV	
(TBHIV),	TB	and	diabetes	(TBDM)	or	TB,	diabetes	and	HIV	(TBDMHIV).	Participant	
characteristics	and	chest	radiograph	features	(outcome	measure)	were	described	using	
simple	proportions	for	the	overall	sample,	as	well	as	by	stratifying	by	these	TB	categories.	
Proportion	of	radiograph	features	by	TB	category	were	compared	using	Chi	squared	test	and	
Fishers	exact	test	as	appropriate.			
	
Multivariate	analysis	and	model	building:	
Multivariate	analysis	was	used	to	calculate	the	association	between	participants	with	TBDM,	
TBHIV	and	TBDMHIV	and	atypical	features	of	TB	chest	radiography:	lower	lung	field	
opacification,	lower	lung	field	cavitation	and	isolated	lower	lung	field	lesions.	Models	were	
built	using	forward	selection	methods.	The	log	likelihood	ratio	test	was	used	to	compare	
nested	models,	by	testing	the	difference	in	the	deviance	between	the	two.	The	model	with	a	
log	likelihood	ratio	test	with	a	high	Chi	squared	value	and	a	P-value	<	0.05	was	considered	the	
most	appropriate	model.	The	Akaikes	Information	Criterion	(AIC)	was	used	to	compare	non-
nested	models	with	the	best	model	having	the	lowest	AIC.	HIV	and	the	interaction	between	
DM	and	HIV	were	included	in	the	model	so	as	to	explain	the	association	between	atypical	
radiographic	findings	and	participants	with	TBHIV	and	TBDMHIV.	Other	interactions	between	
confounding	and	exposure	variables	were	tested	but	none	were	found	to	be	significant.	To	
assess	overall	fit	of	the	models	the	Pearson	goodness-of-fit	test	was	used	with	a	P-value	>	
0.05	indicating	good	fit.		
	
Model	diagnostics:	
The	three	aspects	of	the	model	which	need	to	be	checked	are:	the	form	of	the	linear	
predictor,	the	adequacy	of	the	link	function	and	outlying	or	influential	observations.	The	form	
of	the	linear	predictor	was	checked	by	creating	scatterplots	of	the	Pearson	and	deviance	
residuals	against	the	index	number,	where	a	systematic	pattern	would	denote	an	incorrect	
model.	The	logit	link	function	is	deemed	appropriate	for	all	binary	responses	and	hence	does	
not	require	checking.	Observations	where	their	standardised	residuals	lay	outside	+2	and	-2	
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were	considered	outlying	observations.	These	were	visualized	by	creating	a	scatterplot	of	
standardized	residuals	against	the	index	number.	Influential	observations	were	identified	
using	the	hi	,	a	measure	of	how	far	the	covariate	pattern	lies	from	the	average	covariate	
pattern	and	hence	how	influential	it	is	on	the	model.	Multicollinearity	was	assessed	using	the	
variance	inflation	factor	(VIF)	with	a	VIF	>>>	10	indicating	the	presence	of	multicollinearity.		
	
Model	Building	Table	D-7.1:	Lower	lung	field	opacities	and	TB	category	
	
Lower	Lung	Field	opacities	 	 Log	likelihood	ratio	test	
MODEL	 vs	 Variable	included	 log	likelihood	 AIC	 χ2	 P-value	
A	 -	 Lower	lung	field	
(LLF)	opacity	+	
Diabetes	
-227.4112						 458.8223	 -	 -	
B	 A	 Age	Category	 -226.1947	 462.3894	 2.43	 0.4875	
C	 A	 Smoker	 -225.7972	 457.5943	 3.23	 0.0724	
D	 A	 Previous	TB	 -223.5753			 453.1507	 7.67	 0.0056	
E	 A	 sex	 -227.3298				 460.6595	 0.16	 0.6866	
F	 A	 Age		 -227.2344			 460.4688	 0.35	 0.5521	
G	 A	 HIV	 -224.727					 455.454	 5.37	 0.0205	
Model	D:	LLF	
opacity	+	Diabetes	+	
Previous	TB	+…	
	 	 	 	 	 	
H	 D	 Age	Category	 -222.457	 456.9139	 2.24	 0.5247	
I	 D	 Smoker	 -221.1893	 450.3787	 4.77	 0.0289	
J	 D	 sex	 -223.5726	 455.1452			 0.01	 0.9411	
K	 D	 Age		 -223.5586	 455.1173	 0.03	 0.8550	
L	 D	 HIV	 -220.2727	 448.5453	 6.61	 0.0102	
Model	L:	LLF	opacity	
+	Diabetes	+	
Previous	TB	+	HIV+…	
	 	 	 	 	 	
M	 L	 Age	Category	 -219.6594	 453.3187			 1.23	 0.7466	
N	 L	 Smoker	 -217.4147	 444.8294	 5.72	 0.0168	
O	 L	 sex	 -220.1067	 450.2135	 0.33	 0.5646	
P	 L	 Age		 -220.2587			 450.5175	 0.03	 0.8675	
Model	N:	LLF	
opacity	+	Diabetes	+	
Previous	TB	+	HIV+	
Smoker…	
	 	 	 	 	 	
Q	 N	 Age	Category	 -216.44			 448.88	 1.95	 0.5830	
R	 N	 Sex		 -217.3756				 446.7512	 0.08	 0.7798	
S	 N	 Age	 -217.3902	 446.7805	 0.05	 0.8250	
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Final model: 
logit  opLL DM hi DMhi prevTB smoker, or 
 
Iteration 0:   log likelihood = -227.71326   
Iteration 1:   log likelihood = -215.58356   
Iteration 2:   log likelihood = -215.54396   
Iteration 3:   log likelihood = -215.54395   
 
Logistic regression                               Number of obs   =        330 
                                                  LR chi2(5)      =      24.34 
                                                  Prob > chi2     =     0.0002 
Log likelihood = -215.54395                       Pseudo R2       =     0.0534 
 
------------------------------------------------------------------------------ 
        opLL | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
          DM |   1.708838    .971891     0.94   0.346     .5605123    5.209745 
          hi |   .6340933    .174845    -1.65   0.099     .3693539    1.088588 
        DMhi |   .2692039   .1882827    -1.88   0.061     .0683512     1.06027 
      prevTB |   2.176119   .5696798     2.97   0.003     1.302714    3.635098 
      smoker |   .5062937   .1430596    -2.41   0.016     .2909947    .8808867 
       _cons |   1.561431   .3812124     1.83   0.068     .9676266    2.519635 
------------------------------------------------------------------------------ 
 
. estat gof 
 
Logistic model for opLL, goodness-of-fit test 
 
       number of observations =       330 
 number of covariate patterns =        14 
              Pearson chi2(8) =         6.72 
                  Prob > chi2 =         0.5666 
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Model	Building	Table	D-7.2:	Lower	lung	field	cavities	and	TB	category	
 
 
Lower	Lung	field	Cavities	 	 Log	likelihood	ratio	test	
MODEL	 vs	 Variable	included	 log	
likelihood	
AIC	 χ2	 P-value	
A	 -	 Lower	lung	field	cavity	+	Diabetes		 -109.1866	 222.3732	 	 	
B	 A	 Age	Category	 -109.1264	 228.2527	 0.12	 0.9893	
C	 A	 Smoker	 -109.1762				 224.3525					 0.02	 0.8854	
D	 A	 Previous	TB	 -106.589			 -106.589			 5.20	 0.0226	
E	 A	 sex	 -109.1555			 224.3111	 0.06	 0.8031	
F	 A	 Age		 -109.0932	 224.1865	 0.19	 0.6656	
G	 A	 HIV	 -109.1811	 224.3623			 0.01	 0.9166	
Model	D:	
Diabetes	+	
Previous	
TB	+…	
	 	 	 	 	 	
H	 D	 Age	Category	 -106.4944	 224.9888	 0.19	 0.9793	
I	 D	 Smoker	 -106.4848	 220.9697	 0.21	 0.6481	
J	 D	 sex	 -106.5874			 221.1749	 0.00	 0.9557	
K	 D	 Age		 -106.5866				 221.1732	 0.00	 0.9447	
L	 D	 HIV	 -106.5552					 221.1104	 0.07	 0.7949	
 
As	no	additional	variables	improved	the	baseline	model,	HIV	and	DM*HIV	were	added	to	
model	D	to	create	model	M	
Lower	Lung	field	Cavities	 	 Log	likelihood	ratio	test	
MODEL	 vs	 Variable	included	 log	likelihood	 AIC	 χ2	 P-value	
M	 -	 Diabetes	+	Previous	TB	+	HIV	+	
DM*HIV	
-104.8373						 219.6747	 -	 -	
N	 M	 Age	Category	 -104.6142	 225.2284	 0.45	 0.9305	
O	 M	 Smoker	 -104.6589	 221.3178	 0.36	 0.5503	
P	 M	 sex	 -104.8371	 221.6743	 0.00	 0.9835	
Q	 M	 Age	 -104.7822	 221.5643	 0.11	 0.7397	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 94	
 
Final model: 
. logit  cavLLplus DM hi DMhi prevTB, or 
 
Iteration 0:   log likelihood = -109.45792   
Iteration 1:   log likelihood = -105.58037   
Iteration 2:   log likelihood = -104.83906   
Iteration 3:   log likelihood = -104.83734   
Iteration 4:   log likelihood = -104.83734   
 
Logistic regression                               Number of obs   =        330 
                                                  LR chi2(4)      =       9.24 
                                                  Prob > chi2     =     0.0553 
Log likelihood = -104.83734                       Pseudo R2       =     0.0422 
 
------------------------------------------------------------------------------ 
   cavLLplus | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
          DM |   3.919156   2.647622     2.02   0.043     1.042691    14.73091 
          hi |   1.391283   .6799605     0.68   0.499     .5338366    3.625955 
        DMhi |   .1610133   .1658462    -1.77   0.076     .0213851    1.212306 
      prevTB |   2.138036   .8020291     2.03   0.043     1.024965    4.459861 
       _cons |   .0631255   .0280699    -6.21   0.000     .0264061     .150906 
------------------------------------------------------------------------------ 
 
. estat gof 
 
Logistic model for cavLLplus, goodness-of-fit test 
 
       number of observations =       330 
 number of covariate patterns =         8 
              Pearson chi2(3) =         3.96 
                  Prob > chi2 =         0.2662 
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Model	Building	Table	D-7.3:	Isolated	Lower	lung	field	Involvement	and	TB	category	
 
 
Isolated	Lower	Lung	field	Involvement	 	 													Log	likelihood	ratio	test	
MODEL	 vs	 Variable	included	 log	likelihood	 AIC	 χ2	 P-value	
A	 -	 Isolated	lower	lung	field	involvement	+	Diabetes		 -94.31578			 192.6316	 	 	
B	 A	 Age	Category	 -92.82771	 195.6554	 2.98	 0.3953	
C	 A	 Smoker	 -93.91446			 193.8289	 0.80	 0.3703	
D	 A	 Previous	TB	 -94.19769			 194.3954				 0.24	 0.6270	
E	 A	 sex	 -93.7355			 193.471	 1.16	 0.2813	
F	 A	 Age		 -94.21573	 194.4315	 0.20	 0.6546	
G	 A	 HIV	 -93.43261	 192.8652	 1.77	 0.1838	
 
As	no	additional	variables	improved	the	baseline	model,	HIV	and	DM*HIV	were	added	to	
model	A	to	create	model	H	
 
Isolated	Lower	Lung	field	Involvement	 	 								Log	likelihood	ratio	test	
MODEL	 vs	 Variable	included	 log	
likelihood	
AIC	 χ2	 P-value	
H	 -	 Isolated	lower	lung	field	involvement	+	Diabetes	+	HIV	+	
DM*HIV		
-93.01717					 194.03
43			
	 	
I	 H	 Age	Category	 -91.07533			 196.15
07	
3.88	 0.2743	
J	 H	 Smoker	 -92.65318							 195.30
64	
0.73	 0.3935	
K	 H	 Previous	TB	 -92.79132			 195.58
26	
0.45	 0.5015	
L	 H	 sex	 -92.73194	 195.46
39	
0.57	 0.4501	
M	 H	 Age		 -92.95765	 195.91
53	
0.12	 0.7301	
 
No	other	variables	significantly	improved	the	model.	Hover,	when	running	model	diagnostics	
model	H	had	a	poor	fit	(Pearson’s	Chi	<0.001).	We	therefore	included	previous	TB	in	the	
model	as	this	had	contributed	to	atypical	lower	lung	field	lesions	in	both	the	previous	models.		
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Final Model: 
logit onlyLL DM hi DMhi prevTB, or 
 
Iteration 0:   log likelihood =  -95.84989   
Iteration 1:   log likelihood =  -93.06948   
Iteration 2:   log likelihood = -92.791721   
Iteration 3:   log likelihood = -92.791318   
Iteration 4:   log likelihood = -92.791318   
 
Logistic regression                               Number of obs   =        330 
                                                  LR chi2(4)      =       6.12 
                                                  Prob > chi2     =     0.1906 
Log likelihood = -92.791318                       Pseudo R2       =     0.0319 
 
------------------------------------------------------------------------------ 
      onlyLL | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
          DM |   4.899458   4.222524     1.84   0.065     .9048006    26.53037 
          hi |   2.667727   1.716598     1.52   0.127     .7558232    9.415916 
        DMhi |   .3581676    .368689    -1.00   0.319       .04763    2.693347 
      prevTB |   .7367688   .3411842    -0.66   0.509     .2972729    1.826027 
       _cons |   .0397895   .0236191    -5.43   0.000     .0124306    .1273629 
------------------------------------------------------------------------------ 
 
. estat gof 
 
Logistic model for onlyLL, goodness-of-fit test 
 
       number of observations =       330 
 number of covariate patterns =         8 
              Pearson chi2(3) =         2.72 
                  Prob > chi2 =         0.4365 
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